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1. Introduction
The word “melanoma” was first used by Rene Laennec, inventor of the stethoscope, in his
manuscript reporting a case of disseminated melanoma in 1812 [1]. Cutaneous malignant
melanoma  (CMM)  arises  from  the  malignant  transformation  of  the  pigment  producing
melanocytes,  which  are  located  and  evenly  distributed  in  the  basal  epidermal  layer  of
human skin. These pigment-producing cells (melanocytes) are located predominantly in the
skin, but also found in the eyes, ears, GI tract, leptomeninges, and oral and genital mucous
membranes [2].
The incidence of cutaneous malignant melanoma has increased significantly among all
Caucasian populations over the last several decades. The rate of incidence of cutaneous
melanoma continues to rise almost inexorably in populations of European origin worldwide.
Diagnosis of melanoma at an early stage is almost curable but there is currently no effective
treatment for advanced melanoma. Probably a large proportion of melanomas can be ascribed
to a single (modifiable) risk factor-sun exposure. It has not been established whether medical
intervention of any kind influences the outcome in the case of melanoma. Major initiatives in
recent years have concentrated on education about sun avoidance, the importance of skin
awareness and skin examination, and the screening of populations at high risk for melanoma.
However, it is unclear whether any of the latter measures have had any significant influence
on mortality from melanoma. The annual increase in incidence rate varies between popula‐
tions, but in general has been in the order of 3–7% per year for fair-skinned Caucasian
populations. CMM represents a significant and growing public health burden because of the
increase in incidence and the consequent mortality [3].
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The cancer statistic in the United States was reported to be 6 cases per 100.000 inhabitants at
the beginning of the 1970s and 18 cases per 100.000 and year at the beginning of 2000, thus
demonstrating a threefold increase in incidence rates. Incidence rates in central Europe
increased in the same time period, from 3 to 4 cases to 10 to 15 cases per 100.000 inhabitants
and year, which is very similar to the increase in the United States. The highest incidence rates
were reported in Australia and New Zealand, with 30 to 60 cases per 100.000 inhabitants and
year [4]. Cutaneous melanoma ranks as the sixth most common cancer in American men and
women, the second most common cancer in patients between the ages of 20 and 35, and the
leading cause of cancer death in women ages 25 to 30 years [5]. Although melanoma accounts
for 5% of all skin cancers in the United States, it is responsible for the most common skin cancer-
related deaths (it accounts for 79 percent of all skin cancer deaths) because of its high mortality
when identified at an advanced stage [6, 7]. The number of deaths due to CMM has also
increased in most fair-skinned populations throughout the world in the past few decades.
However, melanoma mortality rates have been rising at a rate of increase lower than that for
melanoma incidence. Between 1955 and 1984, mortality from CMM had been rising both in
young adults (20–44 years) and in middle-aged populations (45–64 years) in most European
countries, North America, Australia and New Zealand, with a rate of increase of 2–4%
annually. In Australia in 1985–1999 the mean age-standardized mortality rates were 4.8 and
2.5 per 100.000 in men and women, respectively. In 1990–1994 the rate rose by 3.7% in men to
5.0 per 100.000 and in women it fell by 5.2% to 2.4 per 100.000 [3]. Although mortality rates
have increased, 5-year survival has steadily improved over recent decades, and is now greater
than 85%, but melanoma causes disproportionate mortality in those of young and middle age,
such that an average of 18.6 years of potential life are lost for each melanoma death in the USA,
one of the highest rates for adult-onset cancers [8]. Predicted 1-year survival for stage IV disease
ranges between 41% and 59% [5].
The etiology of melanoma is multifactorial that environmental, host, and genetic factors
contribute to its development. The most important environmental risk factor is ultraviolet
radiation (UVR) exposure [6]. Most melanomas are thought to be caused by periodic, intense
sun exposure (particularly during the critical time period of childhood and adolescence),
termed the intermittent exposure hypothesis, though exposure in adulthood certainly also plays
a part. In older people, melanomas appear to be more related to chronic exposure. This is
suggested by the body site distribution of melanomas in the elderly, with more melanomas on
chronically exposed body sites [7, 9]. The most important host risk factor for CMM in fair-
skinned people is the presence of both common acquired and atypical (dysplastic) melanocytic
naevi. Patients with a family history of melanoma are at increased risk. Around 5–12% of
patients with melanoma have a family history of CMM in one or more first-degree relatives.
Some of these patients have an inherited mutation in highly penetrant susceptibility genes
which are associated with a significantly increased risk of melanoma [3].
Cutaneous malignant melanoma is currently classified into four major clinical subtypes:
Superficial spreading, nodular, acral lentiginous, and lentigo maligna, of which superficial
spreading melanoma is by far the most common form (approximately 70%) of CMM [10]. CMM
that is less invasive and locally defined at diagnosis has a five-year survival rate of more than
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95% after treatment by surgical excision alone. Fortunately, the vast majority of CMM
(approximately 80%) are diagnosed at this early stage. If the cancer is more advanced, however,
survival rates drop substantially to 30% to 60% after five years, depending on the tumor
thickness in millimeters (Breslow's depth). Metastatic disease has poor patient outcomes as
treatment options are limited [10].
The prognosis for a patient with a newly diagnosed cutaneous melanoma depends mainly on
two factors— the thickness of the primary tumour and the presence or absence of metastasis
to regional lymph nodes. However, other prognostic factors are very important, including
tumour ulceration, mitotic rate, and presence of regression, as well as sex and age of the patient,
and tumour site [8].
For the primary prevention, physical protection from exposure to sunlight is generally
accepted as the most important element of melanoma risk reduction. It seems particularly
meaningful to prevent multiple erythemas during childhood, convincing parents and care
takers not to let children stay too long under the sun. Sun-protective clothing and hats should
be worn and peak hours of sun intensity should be avoided. For these purposes, mass media
campaigns and widespread public education programmes would be most effective to make
changes in attitude and behaviour towards sun protection [8,11]. The wavelength of light that
is causal for melanoma is still not known and therefore sunscreens should be broad-spectrum
types, providing protection across both UVB and UVA ranges. Advice should be to use
sunscreens that are water proof, and sunscreens must be applied regularly and in sufficient
quantities [12]. Regular screening of the total population for CMM does not seem useful and
is not propagated in any country in the world. However, it seems likely that people with a
familial risk of developing melanomas (those with familial or sporadic dysplastic naevus
syndrome, xeroderma pigmentosum and large congenital naevi, representing approximately
10% of all melanoma patients) can benefit from regular check-ups. Screening in these popu‐
lations, and regular checks (every 6–12 months) lead to earlier detection [11].
2. Etiopathogenesis
2.1. Risk factors
The etiology of melanoma is multifactorial, with environmental, host, and genetic factors
contributing to its development. Ultraviolet radiation exposure is the most important envi‐
ronmental risk factor [6]. The precise type of sun exposure that is causal has been controversial
but the data are now strong that the dominant cause is intermittent sun exposure [12]. Periodic
and intense sun exposure rather than long, heavy sun exposure especially during childhood
and adolescence is the feature of intermittent sun exposure. Also, sunburn history particularly
blistering and peeling burns are important indicators for intermittent sun exposure [7].
In a meta-analysis by Dennis et al., an increased risk of melanoma was seen with an increasing
number of sunburns for all time-periods, including childhood, adolescence, adulthood, and
lifetime [13]. The relationship between melanoma and exposure to ultraviolet light is complex
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that lower incidence of melanoma among people who work outdoors is seen compared with
those working indoors. The possible explanation for this is that chronically tanned skin is less
melanoma-prone than untanned skin exposed to bursts of high intensity sun, in particular
sunburns [14].
The geographic distribution of melanoma supports the importance of UVR exposure in its
pathogenesis. Living closer to the equator, where there is the greatest ambient solar radiation,
is consistently associated with increased melanoma risk [6]. When the incidence and mortality
rates of melanoma compared between Europe and Australia it was reported 5 to 10 times
higher incidence rates in Australia [4]. Melanoma incidence and mortality among Caucasians
correlate inversely with latitude of residence and dose of UV radiation, termed latitude
gradient. In the United States, SEER (Surveillance Epidemiology and End Results) data from
1992 to 2001 demonstrate that the latitude gradient applies only to non-Hispanic whites;
melanoma incidence was not associated with latitude and UV index in Afro-Americans,
Hispanics, Asians and Native Americans [7]. Migration studies also provide evidence for the
effect of ambient UVR exposure levels on melanoma risk [6]. Younger migrants to sunny areas
have an increased risk for melanoma as compared with adult immigrants [7].
The anatomic distribution of melanoma also offers insight into the pathogenesis of the disease
and the role of UVR. The most common sites for melanoma are the trunk in men and the lower
legs in women which are areas of high levels of acute, intermittent sun exposure. In older
people, there is a greater incidence of melanomas located on chronically sun exposed areas
with maximal cumulative sun exposure that the face is the most common location [6,7].
Cust et al. reported that UV radiation exposure from sunbeds is a risk factor for early-onset
melanoma, particularly melanoma diagnosed between ages 18 and 29 years [15]. Artificial
lights (psoralen and ultraviolet A light (PUVA), UVB and tanning booths) have been associated
with the development melanoma [7].
Weaker phenotypic risk factors are related to; the presence of skin that burns easily in the sun
such as: skin phototype I-II, high density of freckles, fair complexion/sun sensitivity, an
increased number of common or atypical/dysplastic nevi (moles), blue eye colour and red hair
colour [12]. Loria et al. reported that the crude relative risk increased significantly for individ‐
uals with red hair, but hair color was no longer significant in multivariate analysis and light-
colored eyes were an independent risk factor even after controlling for the number of nevi,
skin type, and other relevant factors [16].
The strongest phenotypic risk factor for melanoma is the presence of increased numbers of
melanocytic naevi [12]. With growing numbers of melanocytic nevi, the melanoma risk
increases nearly linearly. In addition, the presence of atypical melanocytic nevi was found to
be an independent risk factor [4]. Adults with more than 100 clinically typical-appearing nevi,
children with more than 50 typical-appearing, and any patient with atypical nevi are at risk.
Large congenital nevi are recognized potential precursors of melanoma, although the degree
of risk varies depending on the size of the lesion [7]. Twin studies have provided strong
evidence that naevus number is predominantly genetically determined with a smaller effect
of environmental factors, particularly sun exposure. It is theorized, therefore, that the genes
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that determine naevus number are also common melanoma susceptibility genes [12]. Many of
the oncogenic mutations initially identified in melanomas have also been detected in benign
melanocytic proliferations [5].
Any family history increases the risk of melanoma. Familial melanoma comprises 10-15% of
all patients with melanoma [7,12]. The presence of more than one case of melanoma in a family
may occur by chance alone, or may be due to low penetrance alleles and/or sun exposure habits
common to affected relatives. However, an estimated 25% of familial melanoma is associated
with germline mutations of the CDKN2A gene on chromosome 9 (which codes for the cell
cycle inhibitor protein, p16) and often presents with an autosomal dominant pattern of
transmission [17].
2.2. Genetics
Melanoma develops as a result of accumulated abnormalities in genetic pathways within the
melanocyte. These abnormalities promote cell proliferation and prevent normal pathways of
apoptosis in response to DNA damage [8]. The driving force behind the initiation and
progression of melanoma development is the acquisition of somatic mutations in key regula‐
tory genes. The first gene found to be specifically altered in melanoma was NRAS, which
harbors mutations in 15–25% of melanoma cell lines and primary tumors [14]. NRAS mutations
tend to occur in melanomas arising from intermittently sun-exposed skin [5]. NRAS mutations
are more common in patients with nodular melanomas and melanomas arising on chronically
sun-damaged skin. Recent data have shown that NRAS mutations may be associated with
thicker tumors (>1 mm) and higher mitotic rate (>1/mm2) compared with mutations in
BRAF. In response to a variety of cellular stimuli, including ligand-mediated activation of
receptor tyrosine kinases (RTKs), RAS assumes an activated, GTP-bound state, leading to
recruitment of RAF to the plasma membrane and phosphorylation-driven activation of the
RAF-MEK-ERK cascade [14]. RAS genes acquire their transforming activity following the
acquisition of a single-point mutation that impairs their GTPase activity and leads to constit‐
utive signaling through the mitogen-activated protein kinase (MAPK), PI3K/AKT, and Ral-
GDS pathways [18]. Omholt et al. demonstrated that NRAS mutations are present in the radial
growth phase (RGP) of primary melanoma lesions as well as in tumor-associated nevi and that
they are preserved in corresponding vertical growth phase (VGP) and metastatic lesions [19].
BRAF is a serine/threonine kinase, which is a major player in the Ras-Raf-Mek-Erk mitogen-
activated protein kinase (MAPK) signaling transduction pathway that regulates cell growth,
proliferation, and differentiation in response to various stimuli [7]. Mutations in BRAF have
been found in about 60% of melanoma samples and cell lines. BRAF mutations are common
in benign and dysplastic nevi pointing to a potential initiating role of BRAF in melanocyte
transformation [20]. BRAF mutations are more common in intermittently UV-exposed skin
compared with chronically sun exposed skin or relatively unexposed skin (eg, acral sites,
mucosal sites), which more frequently demonstrate KIT mutations. Acral and mucosal
melanomas have infrequent BRAF mutations, and show greater numbers of chromosomal
aberrations. There can also be frequent gains in CCND1 and regions of chromosome 22, and
losses from chromosome 4q. Curtin et al. demonstrated that melanomas arising on skin without
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chronic sun-induced damage had frequent mutations in BRAF and frequent losses of chro‐
mosome 10, whereas melanomas on skin with chronic sun-induced damage had infrequent
mutations in BRAF and frequent increases in the number of copies of the CCND1 gene [21].
Omholt et al. demonstrated that BRAF mutations occur at an early stage during melanoma
pathogenesis rather than being associated with metastasis initiation. Although the BRAF
mutations do not seem to be important for metastasis initiation, the finding that they are
preserved throughout tumor progression suggests that they may still influence tumor
maintenance [19]. Although BRAF mutations are highly prevalent (59%) in melanomas
occurring on skin without chronic sun damage, BRAF mutations are significantly less frequent
in acral and mucosal melanomas. BRAF mutations are more commonly detected in superficial
spreading melanomas and melanomas that arise on nonchronically sun-damaged skin [5].
The two recognized major melanoma susceptibility genes, CDKN2A, located on chromosome
9p21.3, and CDK4 both, are involved in controlling cell division. CDKN2A mutations are found
in approximately 20% of tested melanoma families, while CDK4 mutations have been found
to date in only a few families. CDKN2A encodes for two gene products, p14ARF (alternative
reading frame) and p16 (also known as INK4A, inhibitor of kinase 4a), which regulate cell cycle
entry at the G1 checkpoint and stabilize p53 expression [18, 22, 23]. When defective, p16 is
unable to inactivate CDK4 and CDK6, which phosphorylate Rb, releasing the transcription
factor E2F and leading to cell cycle progression [8].
The PTEN gene, located on chromosome 10, encodes a tumor suppressor protein and has also
gained considerable attention as the understanding of melanoma pathogenesis has increased
[24]. The negative regulation of cell interactions with the extracellular matrix could be the way
PTEN phosphatase acts as a tumor suppressor. PTEN gene plays an essential role in human
development. Mutations in PTEN are found in 10%-20% of primary melanomas and have also
been associated with thyroid, breast, and prostate cancer [5,25]. PTEN encodes a negative
regulator of extracellular growth signals that are transmitted via the phosphatidylinositol-3-
kinase (PI3K)-AKT pathway [14]. Inactivation of PTEN allows signaling through the AKT
pathway, which contributes to aberrant cell growth and escape from apoptosis [5].
3. Epidemiology
Generally, an individual's risk for developing melanoma depends on two groups of factors;
intrinsic and extrinsic that is environmental. "Intrinsic" factors are generally an individual's
family history and inherited genotype, while the most relevant environmental factor is sun
exposure. Epidemiologic studies suggest that exposure to ultraviolet radiation (UVA and
UVB) is one of the major contributors to the development of melanoma. UV radiation causes
damage to the DNA of cells, typically thymine dimerization, which when unrepaired can
create mutations in the cell's genes. When the cell divides, these mutations are propagated to
new generations of cells. If the mutations occur in protooncogenes or tumor suppressor genes,
the rate of mitosis in the mutation-bearing cells can become uncontrolled, leading to the
formation of a tumor [26].
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Cutaneous malignant melanoma is the most serious form of skin cancer. In general, cutaneous
melanoma most commonly affects adult Caucasians and is rarely observed before puberty.
Melanoma may occur at any age, although children younger than age 10 years rarely develop
a de novo melanoma. It was reported that in 2002 there were 53.600 new cases, and 7.400 deaths
from cutaneous malignant melanoma in the United States. The incidence rate of MM has
increased 4% per year since 1973 [27]. This epidemic of MM is also evident in other parts of
the industrialized world, including Australia and southern Europe. It is predicted that the
incidence of MM will continue to increase as a result of the continuing decrease in the
concentration of stratospheric ozone and increasing leisure time for sunlight-related recrea‐
tion, including sunbathing, which increases exposure to solar UV radiation [28].
3.1. Environmental factors
Sunlight and most particularly the ultraviolet spectrum of sunlight is the only environmental
factor that has been compellingly implicated as a cause of melanoma [29].
Possible significant elements in determining risk include the intensity and duration of sun
exposure, the age at which sun exposure occurs, and the degree of skin pigmentation. Exposure
during childhood is a more important risk factor than exposure in adulthood [30, 31].
Individuals with blistering or peeling sunburns (especially in the first twenty years of life) have
a significantly greater risk for melanoma. This does not mean that sunburn is the cause of
melanoma. Instead it is merely statistically correlated [32].
Fair and red-headed people, individuals with multiple atypical nevi or dysplastic nevi and
people born with giant congenital melanocytic nevi are at increased risk [33]. Melanoma
incidence is 10–20-fold higher among the fair-skinned than the dark-skinned people. Among
fair-skinned people, melanoma incidence generally increases with proximity to the equator
(some exceptions occur, particularly in continental Europe, where the association is confound‐
ed by pigmentation). Fair-skinned migrants from high- (e.g. the UK) to low-latitude countries
(e.g. Australia) have lower melanoma rates than native-born residents, and vice versa [29].
History of melanoma in melanoma-prone families due to mutations in some genes were found
to greatly increase the risk of a person. (e.g. CDKN2A and CDK4). Patients with a history of
melanoma are at risk of developing a second primary tumor [34, 35].
Looking at the geographical distribution of the incidence of malignant melanoma in Europe
has increased in Northern Europe, especially Scandinavian countries (20.7 per 100.000 person-
year). Incidence rates were lowest in Southern and Eastern Europe for both males and females,
with rates between 5-10 per 100.000 person-year. mortality rates in studies conducted in
Europe (5.1 per 100 000 person-years ranging from 2.5) was found to be different in a lot less.
Death rates lower in women than men had been established. In the 1990s compared the
incidence and mortality rates in southern and eastern Europe, northern and western Europes
have been identified as the highest and lowest [36].
Between the years 1970-2009, a study conducted among young adults in the United States the
incidence of cutaneous melanoma is increasing rapidly, especially among women. This high-
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risk population should be closely monitored constantly [37]. The incidence may be higher due
to melanoma underreporting to cancer registries, particularly for tumors that are diagnosed
and managed in the outpatient setting [38].
While melanoma accounts for roughly 4% of all skin cancers, it causes more than 75% of skin
cancer deaths. Treatment of melanoma in its early stages provides the best opportunity for
cure. In the United States, an estimated approximately 9.000 deaths will occur in 2012.
Melanoma incidence has continued to increase worldwide, with the highest incidence in
Australia and New Zealand. The most recent analysis of global cancer statistics for melanoma,
from 2002, demonstrated a prevalence of 37.7 cases per 100.000 men and 29.4 cases per 100.000
women in Australia and New Zealand, compared with 6.4 cases per 100,000 men and 11.7 cases
per 100.000 women in North America [39].
Differing melanoma incidence between males and females, and the tendency for females
to develop excess melanin pigmentation during periods of hormonal stimulation such as
pregnancy,  has  led  to  a  number  of  studies  investigating  the  role  of  pregnancy,  oral
contraceptives and hormone replacement therapy both as risk factors for melanoma and
also as events that may affect prognosis. Cumulative data from publications on these topics
provide no evidence that prior pregnancy is a risk factor for melanoma. Similarly, there is
no evidence to indicate that oral contraceptive or hormone replacement use contributes to
melanoma risk, nor that either factor alters the prognosis for those in whom melanoma has
already been diagnosed [40, 41].
3.2. Occupation and melanoma
Airline crews, particularly pilots, have been recorded in a number of studies as having a higher-
than-expected incidence of melanoma. It is suggested that this may be due to greater oppor‐
tunities for recreational sun exposure during regulation breaks between flights in areas of the
world with a high solar exposure [42].
A number of publications show conflicting results concerning the risk of melanoma developing
after renal transplantation and the necessary immunosuppression. Studies from Sweden and
the Netherlands show no increase in melanoma incidence over that expected in these countries
[43], while studies from the USA and UK show a significantly increased risk, 3.6- and 8-fold
higher for USA and UK patients, respectively. While some of these differences may relate to
time frames of studies and changes in immunosuppressive regimes over time, further large
long-term contemporary studies are required to determine the degree of increased cutaneous
surveillance required for transplant patients [44].
3.3. Pesticide exposure
A case–control study comparing melanoma on the palms and soles in both the UK and
Australia observed that melanoma patients reported greater exposure to pesticides than that
reported by controls, and recently, an Italian case–control study has confirmed higher use of
pesticides in a residential setting in melanoma patients compared with that in controls.
Interpretation of these data is complex, as over the past decade there have been many regula‐
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tory changes in Europe regarding the range of pesticides available for domestic use. However,
data from these studies indicate that questions regarding the type and frequency of pesticide
use should be added to future case–control studies [43, 44].
3.4. Genetic factors
Xeroderma pigmentosum (XPD) is a genetic disorder with a mutation of the XPD gene leading
to nucleotide excision repair defects. Patients experience 1000-fold greater risk of melanoma
as they are unable to repair UV-induced DNA damage. The relative ability to repair DNA
modifies the risk in the presence of other host factors such as age, poor tanning ability and
dysplastic naevi. Two polymorphisms of the XPD gene are associated with a decreased risk of
melanoma among women with five or more severe sunburns or high cumulative sun exposure.
Mutations of the melanocortin-1 receptor gene variants are more common among fair-skinned
and red-haired people. Polymorphism of this gene is associated with melanoma. The risky
factors are the phenotype of pigmentation of the individual, the presence of atypical naevi, >50
melanocytic naevi, high recreational and occupational sun exposures [45]. People with a past
history of other types of skin cancer (basal cell carcinomas and squamous cell carcinomas)
caused by high doses of solar UV radiation have threefold higher risks of melanoma than the
average population [46].
3.5. Artificial light
Several forms of artificial light have been associated with the development of melanoma in
some studies: fluorescent lighting and suntan beds and parlors. Although exposure to
fluorescent lighting was hypothesized to increase risk for developing melanoma, there have
been no studies to support this idea. On the other hand, the use of tanning lamps and tanning
parlors may increase risk for melanoma [47, 48].
3.6. Female sex hormones and melanoma
Differing melanoma incidence between males and females, and the tendency for females to
develop excess melanin pigmentation during periods of hormonal stimulation like pregnancy,
have led to a number of studies investigating the role of pregnancy, oral contraceptives and
hormone replacement therapy both as risk factors for melanoma and also as events that may
affect prognosis. Cumulative data from publications on these topics provide no evidence that
prior pregnancy is a risk factor for melanoma. Similarly, there is no evidence to indicate that
oral contraceptive or hormone replacement use contributes to melanoma risk, nor that either
factor alters the prognosis for those in whom melanoma has already been diagnosed [41, 49, 50].
4. Clinical presentation
The most common sites that melanomas are found include the trunk (back) followed by the
upper extremities, and head and neck for men; and the lower extremities followed by the back,
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upper extremities, and head and neck for women. Amelanotic melanoma and those resembling
keratoses are particularly difficult to diagnose without a high index of suspicion. Acral
melanoma is the most frequent form of melanoma among Asians, Africans, and other ethnic
groups of color. Subungual melanoma (SM) is a distinctive variant of acral melanoma that
most often involves the nail bed of the great toe or thumb. Clinical types include;
4.1. Lentigo malign melanoma
Lentigo maligna melanoma is one of the 4 main subtypes of invasive melanoma and constitutes
10 to 15% of cutaneous melanomas. Generally, patients with lentigo maligna are older than 40
years, with a mean age of 65 years. The peak incidence occurs in the seventh to eighth decades
of life [51]. The incidence of lentigo maligna subtypes (in situ and invasive) appears to be rising
in the United States [52].
Sir John Hutchinson first described lentigo maligna in 1890; the disease continues to be called
Hutchinson melanotic freckle on occasion. The lesion has subsequently been characterized as
malignant lentigo of elderly people, junctional nevus, and melanoma in situ. Most authors
currently refer to it as lentigo maligna when it is confined to the epidermis and lentigo maligna
melanoma when it violates the dermis [39].
Lentigo maligna melanoma has evolved from a lentigo maligna.They are usually found on
chronically sun damaged skin such as the face and the forearms of the elderly people. The risk
increases as the number of years spent in sunny districts increases, as well as with increased
hours of exposure to sunlight. The incidence of melanoma is highest in Australia, where lentigo
maligna accounts for 10-15% of all melanomas. Approximately 10-30% of all cutaneous
melanoma arise in head and neck regions. The other risk factors for lentigo malign melanoma
are large or giant congenital naevi, fair skin and history of severe sunburn [53].
Many authors consider lentigo maligna to be a preinvasive lesion induced by long-term
cumulative ultraviolet injury. Conceptually, the term melanoma is used when atypical
melanocytes invade the rich vascular and lymphatic networks of the dermis, thereby estab‐
lishing metastatic potential [12, 51, 53].
Most malignant melanomas arise as superficial tumors confined to the epidermis, which is
often known as horizontal growth. At some point, a stepwise accumulation of genetic abnor‐
malities leads to proliferation and progression to the vertical growth phase, which leads to
dermal and deeper involvement and subsequently nodal metastases [54].
Initially the lentigo maligna is a flat, brown or black, irregularly shaped lesion. These lesions
will grow very slowly, over months or years, and there may be central regression while the
peripheral margin continues to extend. In time, a raised central nodule will develop, indicating
transition to the vertical growth phase [12, 51, 53, 54].
Differantial diagnosis of lentigo malign melanom are solar lentigo, pigmented actinic keratosis,
seborrheic keratosis, common acquired nevi and dysplastic nevi [12].
Lentigo maligna is basically in situ melanoma and is characterized by epidermal atrophy,
extensive solar, lentiginous, and back-to-back proliferation of melanoma cells. Only 5% of
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patients with lentigo maligna progress to lentigo maligna melanoma, and it usually takes
several years. Several methods of therapy can be used to treat lentigo maligna including
cryotherapy, superficial radiation therapy, and surgical excision with mapping and modified
Mohs surgery [55, 56].
Some imaging methods before proceeding to the treatment of lentigo maligna melanoma can
be made. Especially, in patients with suspected metastatic disease, PET scan, CT scan and MR
can be made to detect lymph node and internal organ metastases [57].
The treatment of the melanoma is as for other sites in that the margin of excision for tumours
thinner than 2 mm is 1 cm minimum and for thicker tumours should be 2 to 3 cm. It is
recognized, however, that on the face these margins may not be attainable without unaccept‐
able cosmetic deficit. The surgery is also subject to the same constraints as described above for
lentigo maligna, in that there is a high local recurrence rate of the in situ component [12, 58].
4.2. Superficial spreading melanoma
Superficial  spreading  melanoma  is  the  most  common  type  of  cutaneous  melanoma.  It
accounts for nearly 70% of cutaneous melanoma. The mean age at diagnosis is in the fifth
decade. The commonest sites are the female leg and the male back (Figure 1), but every
site may be affected [12].
Figure 1. Superficial spreading melanoma with characteristic asymmetry, irregular borders.
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Superficial spreading melanoma occurs in two phases: At first, superficial spreading melano‐
ma grows horizontally on the skin surface (radial growth phase). The lesion constitutes as a
slowly-enlarging flat area of discoloured skin. At second, superficial spreading melanoma
becomes invasive, the melanoma cells cross the basal membrane of the epidermis. A rapidly-
growing nodular melanoma can start to proliferate more deeply within the skin [59].
The main risk factors for superficial spreading melanoma are: age, previous invasive melano‐
ma or melanoma in situ, nonmelanoma skin cancer, many melanocytic moles, multiple atypical
naevi, family history of melanoma, fair skin and sun damage. Other risk factors include blue
or green eyes and red or blond hair [60, 61].
Superficial spreading melanoma presents as a slowly growing or changing flat patch of
discoloured skin. At first, it often resembles a mole or freckle. It becomes more distinctive in
time, often growing over months to years or even decades before it is detected. Like other flat
forms of cutaneous melanoma, it can be detected by the ABCDE rule: Asymmetry, border
irregularity, colour variation, large diameter and evolving [51].
The characteristics of superficial spreading melanoma are larger size, irregular shape, variable
pigmentation (colours may include light brown, dark brown, black, blue, grey) and irregular
surface. It is generally greater than 6 mm in diameter. Irregular asymmetric borders are
characteristic [12, 51, 59, 60].
Dermoscopy can be very helpful in distinguishing superficial spreading melanoma from other
skin lesions, such as melanocytic naevi, solar lentigines, seborrhoeic keratoses and pigmented
basal cell carcinoma (Figure 2) [62].
The initial treatment of a primary melanoma is to cut it out; the lesion should be completely
excised with a 2-3 cm margin of normal tissue. Further treatment depends mainly on the
Breslow thickness of the lesion. After initial excisional biopsy; the radial excision margins are
measured clinically from the edge of the melanoma. Occasionally, the pathologist will report
incomplete excision of the melanoma, despite wide margins. This means further surgery or
radiotherapy will be recommended to ensure the tumour has been completely removed [12].
4.3. Acral lentiginous melanoma
Acral lentiginous melanoma (ALM) is a rare variant occuring exclusively on the sole, with the
palm and subungual locations [7, 63]. Subungual melanomas often are mistaken for subungual
hematomas (splinter hemorrhages). Subungual melanoma may show itself as a longitudinal
pigmented band (melanonychia striata) within the nail plate. This variant of melanoma may
also affect the oral and nasal mucosa and involve the anogenital area [64]. This is the least
common subtype of melanoma in white people (2-8% of melanoma cases). It is the most
common subtype of melanoma in dark skinned patients (ie, Afro-American, Asian, and
Hispanic people), representing 29-72% of melanoma cases [65, 66]. Not all palmo-plantar
melanomas are ALMs; a minority are superficial spreading or nodular melanomas [7]. ALM
shows typically as an asymmetric, brown to black macule with variegations in colour and
irregular borders [67]. They usually arise from the nail matrix or, less often, from the nail bed
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or nail fold. ALM is similar to lentigo maligna melanoma in that an irregular pigmented macule
is present for a long time [68].
Although the pathogenesis of ALM remains unknown, it has been theorized that the more
intense and chronic trauma experienced in acral locations may be a predisposing factor [69].
ALM has key demographic and life-style differences to differentiate ALM from other mela‐
noma subtypes: it occurs in an older patient population, and is associated with a lower number
of common and atypical nevi, a lower incidence of familial melanoma, and a lower incidence
of sunburn but a higher personal and family history of noncutaneous cancers [69].
 
Figure 2. Macroscopic view of a superficial spreading melanoma (A), dermoscopic view characterized by blue-white
veil (B).
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There is often a delay in the diagnosis of ALM.The presence of invasion can be deceptive and
may be present in entirely flat lesions [63]. The clinical differential diagnosis of ALM include
a planter wart, which is common reason of delayed diagnosis, black heel (talon noir), lentigines,
melanocytic nevi, tinea nigra, traumatic haemorrhage and tattoos such as by silver nitrate. Any
growing, tender nodule, or an “ulcer” won’t heal, on the sole of the foot, should give rise to
concern that the lesion is a melanoma and biopsy should be considered [12, 70].
4.4. Subungual melanoma
Subungual melanoma, considered a variant of ALM, generally arises from the nail matrix.
They are the most common on the thumb or great toe. It may manifest as diffuse nail discol‐
oration, a longitidunal pigmented band (melanonychia striata) within the nail plate or growth
in the nail bed. Furthermore, 20% of subungual malignant melanomas may present with
amelanocytic lesions rather than melanonychia [7, 71].
Pigment spread to the proximal or lateral nail folds is termed the Hutchinson sign, which is a
hallmark for subungual melanoma. Benign lesions that can mimic subungual melanoma
include longitidunal melanonychia (Figure 3), subungual hematoma, pyogenic granuloma or
even onychomycosis with pigmentation or hemorrhage [7]. Nonresponsiveness to antifungal
drugs should prompt more thorough evaluation, including potential biopsy. Subungual
melanomas are most commonly confused with traumatic hemorrhage. This process is persis‐
tent, often lasting for more than 1 year, but in contrast to melanoma the dark area moves
forward with the nail plate, leaving a normal appearing proximal component. Moreover,
melanoma usually shows distal tapering, with the proximal portion being wider. The possi‐
bility of melanoma should be considered for all pigmented nail bands in fair-skinned patients,
especially if they are darkly pigmented and/or have a width >3mm [67]. If any pigmented
lesion of the nail unit that is strongly suspected of being melanoma, an excisional or incisional
biopsy of the affected area that includes nail matrix should be performed [70].
Overall 5 year survival is disproportionately poor (25-51%) compared to other histological
subtypes [71].
4.5. Nodular melanoma
Nodular melanoma (NM) is the second most common subtype after superficial spreading
melanoma and accounts for approximately 15% to 30% of all melanomas. It is diagnosed most
frequently in patients in their sixth decade of life [63, 67]. NM tends to affect men more than
women. The most common locations are head, neck, the trunk in men (Figure 4) and legs in
women [70].
NM clinically lacks an apparent radial growth phase. It is more common for NM to begin de
novo than to arise in a pre-existing nevus. Typically, it presents as a black or blue-black nodule,
but 5 percent are amelanotic and often misdiagnosed clinically. Thus, any rapidly growing
flesh-colored lesion that persists after 1 month or ulcerates or bleeds should prompt medical
evaluation [7].
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It tends to lack the typical ABCDE melanoma warning signs and thus, may elude early
detection. Histologically, it is believed to lack a preceding radial or in situ growth phase. The
prognosis of NM is generally worse than other forms of melanoma because there is involve‐
ment of the dermis and the lesion is in the “vertical growth phase” at the time of diagnosis.
The clinical differential diagnosis includes hemangioma, pyogenic granuloma, blue nevi,
dermatofibroma, pigmented basal cell carcinoma, as well as other cutaneous neoplasms
(Figure 5). As a general rule, a firm papule or nodule should never be subjected to any form
of monitoring-biopsy if the diagnosis is in doubt [63, 70].
4.6. Mucosal melanoma
Mucosal melanoma is a rare cancer that is clearly distinct from its cutaneous counterpart in
biology, clinical course, and prognosis. It accounts for 1.3%-1.4% of all melanomas; that they
tend to occur near the mucocutaneous junctions of squamous and columnar epithelia. The
most common sites are the head and neck region (conjuctival, intranasal, sinus and oral
cavities), vulva, anorectal, or even urethral melanoma. Activating mutations in the c-KIT gene
are detected in a significant number of patients with mucosal melanoma [72].
Sun exposure does not play a role in the pathogenesis of these lesions. Irritants and carcino‐
genic compounds in the air, such as tobacco smoke and formaldehyde, have been implicated
in the devolepment of head and neck melanoma, the potential role of these compounds is not
clear. The most common presenting trait of mucosal melanoma is the presence of extensive,
Figure 3. Longitidunal melanonychia: longitudinal pigmented band within the nail plate.
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irreguler macular pigmentation. Most mucosal melanomas are lentiginous (mucosal lentigi‐
nous melanoma), followed in incidence by superficial spreading and nodular types.
Because of its hidden location and rich vascularization, mucosal melanoma usually presents
at a more advanced stage and is therefore associated with a higher mortality rate than
cutaneous melanoma [7, 12, 73].
4.7. Childhood melanomas
Childhood melanoma is very rare, particularly before puberty. Approximately 1% to 4% occur
in patients younger than 20 years of age, and only 0.3 to 0.4% occur in pubertal children. After
puberty the incidence of melanoma starts to rise slowly.
As in adults, childhood melanomas mainly affect the white population. Previous surveys have
shown slight female predominance of melanoma in children. The most common primary
tumor sites are the extremities, followed by trunk. Location in head and neck and trunk has
been related to poor prognosis. The risk factors for melanoma in children are parallel those in
adults. There are three known predispositions in childhood melanoma: congenital naevi, the
atypical mole syndrome, familial melanoma and other family cancer syndromes such as
xeroderma pigmentosum and retinoblastoma. Increasing age, UV exposure, and Caucasian
background were also found to be important in pediatric melanoma.
Figure 4. Nodular melanoma manifests as a dark brown-to-black dome-shaped nodule.
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Histologically, childhood melanomas may resemble those of adults, but small cell melanomas
and melanomas with features of Spitz nevus are reported to be more common in this age group.
The differentiation of melanoma from Spitz nevi with atypical features remains a major
challenge for physicians.
Congenital melanoma is extremely rare; most melanomas in children are acquired after birth.
In addition, a mother with visceral metastases can transfer tumor cells transplacentally, giving
birth to a newborn with disseminated metastases.
Although, it seems that pediatric patients with melanoma may have a better prognosis than
adults showing the same type of lesions, a number of children will still develop metastasis and
die of their disease, especially when melanoma is diagnosed after puberty. Treatment follows
the same rationale as in adults, with the aim of early detection and appropriate resection of
the primary melanoma [12, 67, 68, 74, 75].
4.8. Unusual variants of melanoma
4.8.1. Desmoplastic-neurotropic melanoma
Desmoplastic melanoma (DM) is a rare sub-type melanoma that provokes a scar-like tissue
reaction and is frequently associated with neurotropism. It makes up <1% of all melanomas.
It is most commonly develops in older persons and has a male predominance 2:1. The head
Figure 5. Nodular melanoma must be differentiated from pyogenic granuloma, blue nevi, and pigmented basal cell
carcinoma.
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and neck are the most frequently involved sites, although lesions may develop on the trunk
and extremities, palate, gingiva, lip, vulva, anus, and conjunctiva. DMs usually arise on the
skin that has been severely damaged by long-standing sun exposure, although they have been
reported to develop on skin damaged by ionizing radiation and in burn scars [63, 70, 76-78].
Its clinical features are similar to nonmelanoma (keratinocytic) skin cancer. It may occur in
association with macular, lentigo maligna-type pigmentation, or it may present de novo as a
firm, amelanotic nodule or scar. Fifty percent of the time it is amelanotic and may be mistaken
for something as innocent as a scar. In the other 50% of cases it is associated with an overlying
lentigo maligna or superficial spreading melanoma [64, 78]. Lack of pigmentation and clinical
features more suggestive of keratinocytic skin cancer may result in delay in detection and
thicker tumors at diagnosis [39].
Histologically, the tumor is composed of collections of spindle cells diffusely infiltrating the
dermis and often the subcutis, associated with abundant stromal collagen. Many DMs are
deeply invasive at diagnosis and have a tendency to infiltrate perineurally, otherwise called
neurotropic melanoma. Neurotropism is related to increase the frequency of local recurrences.
Also, it seems that neurotropism is associated with a signifiant decrease in survival in patients
with DM. Occasionally, there are some lesions with prominent perineural invasion and no
evidence of an intraepidermal component. These lesions are designated neurotropic melano‐
ma. This seen particularly in lesions on the head and neck area, and may cause severe, relentless
pain. In the recent studies, the percentage of desmoplastic melanomas with neurotropism
ranged from 16.7 to 77.8% [7, 79].
The clinical differential diagnosis is broad, because these lesions often do not have features
that suggest melanoma. Some of the clinical diagnoses that may be rendered include, scar,
basal cell carcinoma, squamous cell carcinoma, fibroma, recurrent nevus, and metastatic
carcinoma. Deep tissue samples are necessary to establish the diagnosis. The use of immuno‐
chemistry (testing for S100 antigen) is suggested as a useful tool in establishing the diagnosis.
This sub-type of melanoma usually lacks any valuable dermoscopic features [12, 76-78].
Local recurrence is common, in 22% to 70% of cases, largely because of the tendency of DM to
exhibit neurotropism. Although deeply invasive, DM is associated with lower metastatic rates
than other sub-types of melanoma when matched for depth of invasion. When they metasta‐
size, these tumors, unlike most melanomas may by-pass regional lymph nodes and spread
hematogenously [7, 64, 70].
4.8.2. Angiotropic melanoma
Angiotropic melanoma is defined by cuffing of (close apposition to) the external surfaces of
either blood microvessels or lymphatic channels by melanoma cells in a pericytic location
without evidence of intravasation in at least two or more foci. Angiotropic metastasis is not
synonymous with vascular invasion. The mechanism of angiotropism of melanoma is not clear.
There may be a special affinity between the tumor cells and the vascular wall. Angiotropism
is seen with greater frequency in melanomas also showing desmoplasia and neurotropism.
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Angiotropism has been suggested to be a prognostic factor strongly predicting risk for
metastasis of melanoma [77, 80].
4.8.3. Nevoid melanoma
Nevoid melanoma describes a heterogeneous grup of rare lesions that they may resemble a
Spitz nevus or an acquired or congenital melanocytic nevus. Nevoid melanoma equally affects
women and men and the mean age of diagnosis is 47 years. It occurs anywhere, but lower
extremities and trunk are preferential sites. Clinically, this may correspond to a tan nodule
typically greater than 1 cm in size, located on the trunk or proximal limbs of a young adult.
Histologically, the architectural pattern appears very similar to that of a compound or
intradermal nevus with an overall symmetry, well-defined lateral margins, minimal or no
intraepidermal pagetoid spread. Histological features mentioning melanoma include the
absence of maturation of dermal tumor cells, slight cytological atypia with some mitoses in
the dermal component [77, 78].
The differential diagnosis includes Spitz nevus, congenital melanocytic nevus, minimal-
deviation melanoma, nodular melanoma and melanoma arising in a dermal nevus. Although
only one study has reported a better biological behavior for this lesion, there is no evidence
that nevoid melanoma has a better prognosis than ordinary melanoma [77, 78, 81].
4.8.4. Verrucous melanoma
Clinically, verrucous melanomas are usually small hyperkeratotic papules without areas of
regression and mimic either a verruca, seborrheic keratosis, or a compound or congenital
naevus. Some studies reported a greater frequency on the extremities of women, but this has
not been confirmed. The back of men also frequently is involved. Histologically, the verrucous
component is represented by marked epithelial hyperplasia. It has the same prognosis as
conventional melanoma [68, 77, 82].
4.8.5. Small cell melanoma
Small cell melanoma describes a heterogeneous group of melanomas arising in different
settings whose common denominator is a population of small cells. A first type, developing
particularly in adults, is comprised of small cells with roundish, hyperchromatic nuclei, slight
cytoplasm, and numerous mitoses resembling Merkel’s cells. A second variant of small cell
melanoma has been described arising de novo in children and adolescent on the scalp or
developing in a congenital nevus. A third type of small cell melanoma has been described in
sun-damaged skin of old patients in the setting of solar melanocytic neoplasia or atypical
lentiginous nevi.
A recent report suggested that a small-cell morphology in melanomas is significantly associ‐
ated with positive sentinel lymph node involvement. Melanomas manifesting this morphology
are invariably in vertical growth phase and have an aggressive course [77, 78, 83].




Spitzoid melanoma is a rare sub-type of melanoma that resembles clinically and histologically
a Spitz nevus. But it tends to be larger and have asymmetry and irregular coloration. It can
occur in children but are more common in adults. Clinically, spitzoid melanomas are changing
nodular lesions, often reaching 1 cm or more in diameter. The nodules are usually amelanotic.
They can mimic hemangiomas, pyogenic granulomas, xanthogranulomas, or basal cell
carcinomas. Less often, the lesions are pigmented and variegated in color. Nodular lesions can
be crusted and ulcerated. The head and extremities are common sites.
Some spitzoid melanomas can evolve from a preexisting Spitz nevus, whereas other spitzoid
melanomas can develop de novo. Differentiation between two of them is sometimes very
difficult, especially in younger patients. The presence of mitoses, the nuclear and nucleolar
pleomorphism of the cells, the asymmetric distribution of the pigment, and an inflammatory
infiltrate with irregular disposition should prompt us to spitzoid melanoma.
The prognosis of spitzoid melanoma in adults is the same as that for other variants of mela‐
noma of equal Breslow thickness [7, 77, 84].
4.8.7. Balloon cell melanoma
Balloon cell malignant melanoma (BCMM) is the rarest histological type of primary cutaneous
melanoma and is composed of large, polyhedral, foamy cells with abundant cytoplasmic
vacuoles. Clinically, lesions appear as soft, rubbery, or firm nodules with a polypoid or
papillomatous contour whose cut surfaces are grayish white or brown. The differential
diagnosis includes balloon cell change in benign nevi including blue nevi and common
acquired nevi, with which balloon cell melanoma may coexist, as well as other malignant clear
cell neoplasms. The presence of cytological atypia, nuclear pleomorphism, and mitoses are
important for its distinction from the more common balloon-cell nevus. The expression of the
usual immunohistochemical markers such as S-100 protein and HMB-54 helps to distinguish
this lesion from other clear cell tumors of the skin. The prognosis is similar to that of other
types of melanoma matched for depth of invasion [70, 77, 78, 85].
4.8.8. Clear cell sarcoma: Melanoma of soft parts
Clear-cell sarcoma (CCS) is a perplexing tumor considered by some authors as a soft tissue
sarcoma derived from the neural crest and by others as an unusual variant or subtype of
melanoma. CCS shows a predilection for the deep soft tissues of the lower extremities close to
the tendon, fascia, or aponeuroses. The tumor presents as a slowly growing deep-seated mass
in close relation with tendons and aponeuroses associated with tenderness and pain. It
generally appears in young adults between the ages of 20 and 40 years.
Histologically, the tumor has a multilobulated apperance made by nests and fascicles of
uniform plump spindle cells seperated by fine to coarse fibrous septa. CCS is an aggressive
neoplasm with a poor prognosis similar to that of sarcomas, with a high rate of local recurrences
and metastases to lymph nodes and lungs. Both survival and distant metastases seem to
correlate with the tumor size more than the histological parameters [12, 67, 77, 86].
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5. Differential diagnosis
Melanoma must be distinguished from a variety of several cutaneous and mucosal lesions.
The differential diagnosis change according to the subtype of melanoma.
5.1. Superficial spreading melanoma
This is the most common type of melanoma. It is usually seen on sun-exposed areas, mostly
on the lower extremities of women, and the upper back of men. Superficial spreading mela‐
noma can present as an irregular macule with variation in color and texture. A papule or nodule
may arise from the macule as the tumor progresses from radial to vertical growth. Superficial
spreading melanoma can present de novo or within a preexisting nevus. Atypical nevus,
melanocytic nevus, lentigo, seborrheic keratosis, Spitz nevus and superficial basal cell carci‐
noma must be distinguished from superficial spreading melanoma [87-89].
There are several features that can aid in distinguishing the common melanocytic nevus from
melanoma. The “ABCD” rule, which has been expanded to the “ABCDE” rule, provides a
helpful aid in the diagnosis of pigmented lesions:
A = Asymmetry
B = Border irregularity
C = Color variegation
D = Diameter greater than 6 mm/Difference
E = Elevation/Evolving
Atypical nevus may be misdiagnosed as melanoma because of focal or minimal pagetoid
spread, confluence of cellular aggregates along the dermal-epidermal junction, prominent
variation  in  nesting  pattern,  significant  cytologic  atypia,  entrapment  of  nests  of  dermal
nevus cells in the papillary dermis,  and dense mononuclear cell  infiltrates.  On occasion,
the distinction of atypical nevus from melanoma is exceedingly difficult. The discrimina‐
tion of melanoma from atypical nevus is usually possible because of the larger size, greater
asymmetry, disorder, cellularity, and cytologic atypia encountered in melanoma. Usually
atypical nevus will maintain an overall symmetry, a nevic appearance as exemplified by
fairly  organized  junctional  nesting,  a  basilar  proliferation  of  melanocytes  that  is  still
concentrated along the epidermal rete and with greater density toward the lower poles of
the rete [89-91]. Melanoma may mimic seborrheic keratoses but also may arise within the
seborrheic keratosis. Spitz nevus is usually domeshaped but may be soft or hard, sessile or
pedunculated. It is usually pink to red but may be brown. In contrast to melanoma, the
patient  can  usually  pinpoint  the  onset  of  the  tumor.  The  nevus  may  persist  but  more
commonly evolves into an intradermal melanocytic nevus. Histologically, the spindle and
epithelioid  nevi  are  characterized  by  a  cellular  uniformity,  as  opposed  to  the  pleomor‐
phism  that  characterizes  malignancy.  The  development  of  an  apparent  spindle  and
epithelioid nevi after puberty should be regarded with concern. [7, 92, 93].




Nodular melanoma is the second common subtype of melanoma. It is mostly seen on trunk.
This type grows rapidly and enlarge. Instead of arising from the nevus, nodular melanoma
begins de novo. Pigmented nodules may be mistaken with blue nevus, pigmented Spitz nevus,
pigmented basal cell carcinoma, squamous cell carcinoma, metastatic melanoma, Kaposi
sarcoma and angiosarcoma. Amelanotic nodules can be mistaken with basal cell carcinoma,
hemangioma, pyogenic granuloma and Merkel cell carcinoma.
Metastatic melanoma is often fairly monomorphous with little stromal response while nodular
melanoma are often polymorphous and exhibits greater stromal response.
The blue nevus is a dark blue or black, hairless, dome-shaped nodule, ranging in diameter
from a few millimeters to several centimeters, but usually measuring about 5 mm. Its color
results from the Tyndall light-scattering effect of light reflected from deeply placed dermal
pigment through the colloidal medium of the dermis. It most commonly occurs on the head
and neck, dorsum of the hands and feet, and buttocks [87, 94, 95].
The keratoacanthoma, in common with the spindle and epithelioid nevus of Spitz, may
produce the sudden onset of a rapidly growing pigmented nodule, a presentation similar to
that of nodular melanoma. Several vascular lesions, including pyogenic granuloma, throm‐
bosed hemangioma, and capillary aneurysm may also produce similar findings.
Kaposi’s sarcoma usually appears as multiple violaceous plaques or nodules on the lower
extremity. Older tumors tend to assume a reddish brown hue, a pigmentation produced by
extravasated red blood cells, and may regress as new ones appear. Ulceration and hemorrhage
are frequently seen [96-98].
When there is a doubt in clinically; dermoscopic images and histopathological examination
must be done and the exact decision must be made by that.
5.3. Lentigo maligna and lentigo maligna melanoma
Lentigo maligna (LM) has a long radial growth phase that may progress to invasive lentigo
malign melanoma. Some authors consider LM as in situ melanoma. Both subtypes are seen in
older population. The most common locations are cheeks, nose, neck and scalp. It is related to
cumulative sun exposure. Most cases presenting as LM remain in situ lesions; these lesions
commonly occur in cosmetically sensitive areas on the head and neck and can abut critical
anatomic sites, such as the eyelids, ears, nose, and lips [7, 87, 88]. In dermoscopic examination;
hyperpigmented follicular opening, annular-granular pattern, pigmented rhomboidal
structures, obliterated hair follicles are seen. Classical dermoscopic features of extrafacial
melanoma (atypical pigment network, irregularly distributed globules, dots, streaks and
pseudopods) and vertical growth phase-associated dermoscopic criteria (ulceration, blue
papular areas and black structureless areas) can also be seen. [99-101].
Lentigo malign melanoma is confused with solar lentigo, ephelids, pigmented actinic keratosis,
solar melanocytic hyperplasia, flat seborrheic keratosis and superficial pigmented basal cell
carcinoma. Solar lentigines and its amount in excess are predisposed to LMM [7, 99]. Ephelids
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appear early in childhood. They darken in the summer in response to UV irradiation and
lighten in the winter. LM develops irregularities of color, margins, and surface characteristics
and enlarges progressively, unlike a common ephelid. Benign lentigines are usually tan to
brown, flat, and oval, measuring 5 to 10 mm in diameter. Lentigines, whether benign or lentigo
maligna, do not fade when shielded from light. Histologically, they are characterized by an
increased number of normal dendritic melanocytes along the dermo-epidermal junction. The
solar lentigo appears on sun-exposed surfaces during middle to late life, in common with
lentigo maligna, and may closely resemble lentigo maligna [87, 94, 102].
5.4. Acral lentiginous melanoma
The frequency of this subtype in various ethnic groups is different from each other. ALM
represents the most common type in darker-pigmented individuals (in blacks 60-72 %, in
Asians 29-46 %). ALM is diagnosed in fifth or sixth decades. The most common sites for ALM
are the soles, palms and subungual locations. Subungual melanoma may be first evident as a
split nail, a swelling of part of the nail bed, an ulceration with a bloody crust, or a longitudinal
black or brown streak in the nail bed. The great toe and thumb are most often affected. ALM
may be confused with plantar wart, hematoma, palmoplantar nevus and pyogenic granuloma.
Subungual melanoma must be differentiated from glomus tumor, hemorrhage, infection,
onychomycosis, Kaposi’s sarcoma, Bowen’s disease, tinea nigra, melanosis and keratoacantho‐
ma [103-106].
Acral lentiginous melanoma, the most common clinicohistologic type of acral melanoma,
shares some histologic features with LMM but differs from LMM in its younger age at onset,
its anatomic site, the absence of chronic sun exposure, and the greater depth of penetration at
diagnosis [71].
The differential diagnosis for acral melanoma primarily includes lentigines and lentiginous
melanocytic nevi of acral skin. Lentigines of acral skin usually do not exhibit the frequency of
melanocytic proliferation or cytologic atypia that is typical of acral melanoma [7, 97].
5.5. Mucosal melanoma
Mucosal melanomas can arise on the head, neck, vulva, anorectal region and even urethra.
With the exception of conjunctiva, patients present with delayed diagnosis. Because of a radial
growth phase manifesting as a macular pigmentation any suspicious area in these locations
must be biopsied. It can be mistaken with melanotic macules, amalgam tattoo, venous lake,
Kaposi’s sarcoma, genital lentiginosis and atypical intraepidermal melanocytic proliferation
[107-109].
Melanoma of the vulva is really mistaken with vulvar melanosis. Lesions of vulvar melanosis
manifest irregular pigmentation with skip areas up to several centimeters in size, but the
borders are regular and sharp. Histologically, vulvar melanosis manifests prominent basal
layer keratinocytic pigmentation with either a normal or slightly increased density of cyto‐
logically basal melanocytes having prominent elongated dendrites. Pigmented Bowen’s disease
manifests hyperkeratosis and comprises nested neoplastic keratinocytes containing melanin
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granules. Oral mucosal melanoma usually presents as an irregular brown patch or mass on
the oral mucosa extending to the gingival margins. Esophageal and nasal mucosal melanomas
are occult and present with obstruction or bleeding [108].
5.6. Desmoplastic melanoma
This subtype is rare and locally aggressive. Commonly it arise in the sixth or seventh decades.
The sun-exposed head and neck regions are most effected parts. The lesions have typically
have a firm, sclerotic, or indurated. One half of these melanomas are amelanotic. Desmoplastic
melanoma is usually diagnosed at an advanced stage, because of the difficulty of its diagnosis.
Sclerosing blue nevus, desmoplastic Spitz nevus, dermatofibroma, leiomyosarcoma, malignant
fibrous histiocytoma, atypical fibroxanthoma, spindle cell squamous cell carcinoma and,
neurothekeoma should be thought in differential diagnosis. The desmoplastic Spitz nevus has
an inverted wedge-shaped pattern, manifesting an admixture of spindle cells with delicate
elongated nuclei and ganglion like cells. Early desmoplastic melanoma shows a infiltrative
pattern of growth in which large atypical hyperchromatic spindle cells deform the dermal
architecture and invade the dermis of hair follicles. The neurotropism and foci of chronic
inflamation that exist in desmoplastic melanoma usually are absent in Spitz nevus [110-112].
5.7. Nevoid melanoma
Nevoid melanoma describes a heterogeneous group of rare lesions that histologically resem‐
bles benign nevus by their symmetry and apparent maturation with descent in the dermis.
Histopathologic features include marked hyperchromasia of the nuclei of tumor cells, the
presence of mitoses, and an expansile growth of the dermal cells with effacement of the
adventitia in affected area. It may be seen as a papule or nodule that is more than 1 cm in
diameter. Minimal deviation melanoma, nodular melanoma, and melanoma arising in dermal
nevus must be considered in the differential diagnosis [51, 87].
5.8. Dermoscopy
Dermoscopy, dermatoscopy, epiluminescence microscopy, diascopy, surface microscopy and
incident light microscopy are all synonym. Dermoscopy is a noninvasive technique in which
a handheld device is used to examine a lesion through a film of liquid, mainly immersion oil,
using nonpolarized light, or the lesion is examined under polarized light without a contact
medium. Digital dermoscopy permits computerized digital dermoscopic images to be
retrieved and examined at a later date so that comparisons could be made and changes detected
over time. Confocal scanning laser microscopy and multispectral digital dermatoscopy are
new imaging instruments used for early detection of cutaneous melanomas. Dermoscopy
improves sensitivity up to 30% and specificity of melanoma diagnosis compared with clinical
diagnosis. Morphologic features which are invisible to the naked eye, could be seen with the
help of this technique.
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Various diagnostic dermoscopic algorithms such as the ABCD rule, the seven-point checklist,
pattern analysis, Menzies method, and CASH (color, architechture, symmetry, and homoge‐
neity) have been developed for cutaneous melanoma.
Melanomas are multicolored in brown colors and other colors such as black, blue, and pink.
Usually a multicomponent pattern of three or more distinctive features can be seen. Atypical
pigment network (Figure 6), irregular dots and globules, irregular streaks (pseudopods, radial
streaming), irregular blotches, blue-white veil, abrupt cut-off of the trabeculae (Figure 7),
regression structures (peppering), and atypical vascular architecture are common in invasive
melanomas.
Figure 6. Irregular pigment network is seen (By the courtesy of Prof. Dr. Oya Oğuz).
Figure 7. Notice the abrupt cut-off of the trabeculae (By the courtesy of Prof. Dr. Oya Oğuz).
Highly specific surface microscopic features of cutaneous malignant melanoma metastases are
as follows: saccular pattern (red-blue, red-light brown, reddish-brownish-gray, blue-gray,
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dark brown to black); gray streaks surrounding the lesion (melanoma cell infarcts); red-brown
globules irregular in size and color; polymorphic angiectatic base pattern and/or aneurysms;
areas of polymorphic ectatic vessels running parallel to the skin surface; peripheral erythema
(red corona); microscopic ovoid blood lakes; and homogeneous pattern (brown or blue to
black) [12, 51, 87].
6. Histopathological examination
Essentially all melanomas begin as a proliferation of melanocytes initially confined to the
epidermis. Increasing cytologic atypia of melanocytes accompanies the aberrant architectural
appearance of melanomas. After the period of intraepidermal proliferation, there is often
invasion of the papillary dermis, primarily as single cells and small aggregates of cells. Breslow
thickness (in mm) of melanoma is one of the most important factors determining prognosis
and theraphy. Melanomas with prominent invasive components may display polypoid
morphologies.
6.1. Lentigomaligna/ Lentigomaligna Melanoma (LM/LMM)
Lentigomaligna (known as Hutchinson’s melanotic freckle) which is the precursor lesion of
LMM is characterized by reproduction of atypical melanocytes mainly present in the basal
layer of the epidermis. Tumor cells contain polygonal-shaped, pleomorphic irregularly
hyperchromatic, angulated nuclei (Figure 8). In approximately 85% of cases of LM, multi‐
nucleated melanocytes are seen in the basal layer. These cells are named as “starburst giant
cell”. The presence of atypical melanocytes in the hair follicles and sweat duct epithelium is a
characteristic feature but sometimes it may lead to difficulties in evaluation of tumor thickness
[109, 113, 114]. Also there is effacement of rete ridges [115]. Due to chronically actinic damage,
epidermis is usually atrophic and solar elastosis is seen in the dermal layer [116]. The upper
part of the dermis usually contains melanophages and lymphocytes to a lesser extent [114]. If
the lesion progresses, pagetoid spread may be observed within the epidermis [109]. When
invasion occurs into the dermis, spindled cells and tumor cell pigmentation can be seen [117].
6.2. Superficial spreading melanoma
Superficial spreading melanoma is also known as pagetoid melanoma which characterized by
a proliferation of atypical melanocytes singly and in nests in all layers of the epidermis [114].
Atypical melanocytes sometimes show “buckshot scatter” within the epidermis (Figure 9)
[113]. The large tumor cells contain dark, atypical nuclei and abundant, pale cytoplasm [118].
The epidermis may have normal or hyperplastic appearance [119]. There is a continuous
spread of tumor growth from one rete ridge to another [114]. If the tumor progresses to vertical
growth phase, microinvasive tumor which contains nested and dispersed cells is seen within
the dermis [109].
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Figure 9. Superficial spreading melanoma: atypical melanocytes are scattered throughout the epidermis. Tumor cells
compose cell groups at basal layer, The melanocytes have abundant eosinophilic cytoplasm and pleomorphic vesicular
nuclei. Nucleoli are prominent (By the courtesy of Dr. Ahmet Cemil Kaur).
6.3. Nodular melanoma
Nodular melanoma has no concomitant or preexisting radial growth phase [109]. It grows
vertically from the beginning and thus may invade the epidermis [113, 114]. Cellular features
include a large nucleoli and frequent mitosis [118]. Epidermal melanocytic proliferation is so
minimal which typically extending less than three epidermal ridges on both sides of tumor
Figure 8. Lentigo maligna: in this in situ lesion, tumor cells are hyperchromatic and distributed in a lentiginous pattern
(By the courtesy of Dr. Ahmet Cemil Kaur).
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[120]. The tumor mass contains small nests and aggregates of atypical melanocytes (Figure
10, 11, 12) [117].
6.4. Acral lentiginous melanoma
Histological changes are not fully clear in the early stages which may be seen irregular
epidermal hyperplasia and dispersed, localized to the basal layer, atypical melanocytes [114].
Atypical cells proliferate as diffuse along to dermoepidermal junction in the radial growth
phase. These cells create a lentiginous pattern by scattered severally [121]. Atypical melano‐
cytes have marked nuclear atypia and also seen around the adnexal structures [109]. In contrast
to acral nevi, pigment is seen throughout the stratum corneum [105]. Other changes in the
epidermis include acanthosis and elongation of the rete ridges.Tumor infiltration of lympho‐
cytes and tumor regression are common findings in ALM. Kim et al. observed that the
frequencies of these findings are 75% and 25% of ALM cases, respectively [122]. The dermal
invasive component is predominantly spindle cell type, but epitheloid or nevoid cells may be
seen. The presence of small nevus cells may indicate a worse prognosis. Additionally lack of
elastosis in dermis is prominent [105, 113, 123].
Figure 10. Nodular melanoma: characteristic melanoma morphology, the tumor is composed of cell groups (By the
courtesy of Dr. Ahmet Cemil Kaur).
6.5. Desmoplastic melanoma
Desmoplastic melanoma is characterized by intensive atypical spindle-shape melanocytes
within dense collagen bundles [124]. Tumor cells have hyperchromatic, elongated nuclei but
usually no contain pigment in their cytoplasm [125, 126]. There are often nodular lymphocytic
aggregates that are helpful in diagnosis [114, 127]. Perineural invasion has been reported in
some studies. In a study by Lens et al., the percentage of desmoplastic melanoma with
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nuerotropism ranged from 16.7% to 77.8% [76]. Kay et al. reported that perineural invasion
was 82% [128]. There are two subtypes of desmoplastic melanoma histologically; i) pure
desmoplastic melanoma that characterized by desmoplasia through out the tumor, ii) and
mixed desmoplastic melanoma that characterized by desmoplasia associated with non-
desmoplastic invasive melanoma [129].
Figure 11. Nodular melanoma: close view, the tumor cells are pleomorphic with abundant cytoplasm, large vesicular
nuclei and prominent nucleoli (By the courtesy of Dr. Ahmet Cemil Kaur).
Figure 12. Nodular melanoma: in this example there is heavy melanin pigmentation (By the courtesy of Dr. Ahmet
Cemil Kaur).
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6.6. Minimal deviation melanoma
Minimal deviation melanoma is a variant of invasive melanoma that characterized by a nodule
with minimal histologic deviation compared to ordinary nevus. It may be confined into the
papillary dermis or may invade into the reticular dermis or beyond. This melanoma variant is
divided into 6 subtypes according to cytological features (Spitz, halo-nevus like, pigmented
spindle cell, desmoplastic, small cell and dermal variant). The average thickness is 3, 40 mm.
The infiltration into the subcutaneous fat tissue is not often seen. Necrosis is absent while
perineural invasion, mitoses and inflammation with desmoplasia can be seen. Mitotic activity
is usually quite low [78, 114, 130, 131].
6.7. Special variants
6.7.1. Follicular melanoma
This rare variant is characterized by a deep-seated follicular structure in which atypical
melanocytic cells extend downward along the follicular epithelium and mainly involves
follicular unit as well as adjacent dermal layer [113, 132, 133].
6.7.2. Myxoid melanoma
Myxoid variant is characterized by spindle and stellate-shaped cells embedded within myxoid
stroma. There is no cytoplasmic mucin in tumor cells. The stroma stains with Alcian blue.
HMB-45 is showed less often while tumor cells strongly express S-100 protein [109, 113].
6.7.3. Balloon cell melanoma
The tumor is composed of large cells that exhibit an abundant quantity of clear or finely
vacuolated cytoplasm. The other histopathological features include nuclear pleomorphism,
mitotic activity, cytological atypia and necrosis [78, 113].
6.8. Histopathologic prognostic factors in melanoma
6.8.1. Tumor thickness
Primary tumor thickness is the most powerful predictor of melanoma survival. The Breslow
thickness that is measured from the most superficial aspect of the granular cell layer to the
deepest point of invasion of the tumor is the better prognostic indicator. If the tumor is
ulcerated, the measurement should be from the base of the ulcer to the deepest dermal
melanoma cell. In AJCC staging system (2001), the thickness thresholds have been revised as
≤1.0 mm, >1.0-2.0 mm, 2.1-4.0 mm and >4 mm. The Breslow thickness increases with increasing
rate of sentinel lymph node involvement: 4% in melanoma smaller than 1.00 mm, 12% in
melanoma 1.01 to 2.00 mm, 28% in melanoma 2.01 to 4.00 mm, and 44% in melanoma exceeding
4.00 mm.
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Clark’s level which is other tumor thickness indicator is described by Clark as anatomic levels
in melanoma invasion (Table 1):
Level I Melanomas confined to the
Level II Penetration by melanomas into
the papillary dermis
Level III Tumor cells fill and expand the
papillary dermis
Level IV Spreading into the reticular
dermis
Level V Penetration into the
subcutaneous fat
Table 1. Clark level of invasion
If Clark’s level increases, the mean life span is decreased [119, 134-137].
6.8.2. Ulceration
Ulceration is defined as disappearance of the all layers of epidermis (including basement
membrane), evidence of host response, and thinning, effacement or reactive hyperplasia of
adjacent epidermis. The presence of ulceration shows that the lesion has aggressive feature.
Ulceration due to trauma should be excluded. The presence of ulceration is associated with a
higher risk of metastases. According to the presence or absence of ulceration, each T category
is divided into two as “a” and “b” in the AJCC cutaneous melanoma classification 2009 (Table
2). This system classifies melanomas on the basis of their local, regional, and distant charac‐
teristics, as follows: [39, 51, 135, 138]
• Stage I and II - Localized primary melanoma
• Stage III - Metastasis to single regional lymph node basin (with or without in-transit
metastases)
• Stage IV – Distant metastatic disease.
6.8.3. Mitotic rate
The mitotic rate is important prognostic indicator that is determined by the number of mitotic
figures/1 mm2 of tumor in the most mitotically active area. The increased mitotic activity is
associated with poor prognosis [51, 114].
6.8.4. Satellite deposites
Microsatellites are defined as discrete tumor aggregates separated from the main body of the
tumor mass. These deposites settled to 0,05 mm or more away from the main tumor mass are
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associated with an increased risk of local recurrence, regional lymph node metastases and
diminished survival [114, 134].
Stage T N M Clinical-Histopathological Features
0 Tis N0 M0 In situ melanoma (ıntraepithelial)
IA T1a N0 M0 ≤1 mm without ulceration
IB T1b N0 M0 ≤1 mm with ulceration
T2a N0 M0 1.01-2 mm without ulceration
IIA T2b N0 M0 1.01-2 mm with ulceration
T3a N0 M0 2.01-4 mm without ulceration
IIB T3b N0 M0 2.01-4 mm with ulceration
T4a N0 M0 4 mm without ulceration
IIC T4b N0 M0 "/>4 mm with ulceration
IIIA T1-4a N1a M0 Single regional nodal micrometastasis, without ulceration
T1-4a N2a M0 2-3 microscopic positive regional nodes, without ulceration
IIIB T1-4b N1a M0 Single regional nodal micrometastasis, with ulceration
T1-4b N2a M0 2-3 microscopic positive regional nodes, with ulceration
T1-4a N1b M0 Single regional nodal macrometastasis, without ulceration
T1-4a N2b M0 2-3 macroscopic regional nodes, without ulceration
T1-4a/b N2c M0 In-transit met(s)/ satellite lesion(s) without metastatic lymph nodes
IIIC T1-4b N1b M0 Single regional nodal macrometastasis, with ulceration
T1-4b N2b M0 2-3 macroscopic regional nodes, with ulceration
Any T N3 M0 4 or more metastatic nodes, matted nodes, or in-transit met(s)/satellite
lesion(s) with metastatic nodes
IV Any T Any N Any
M1
M1a: Distant skin, subcutaneous, or nodal mets with normal LDH levels
M1b: Lung metastases with normal LDH
M1c: All other visceral metastases with normal LDH or any distant metastasis
with elevated LDH
T=tumor size; N=node status; M=metastasis; Ta=without ulceration; Tb=with ulceration;
Table 2. Cutaneous Melanoma Staging
6.8.5. Lymphocytic infiltration
Tumor-infiltrating lymphocytes are an important indicator of host immune response against
melanoma. This response is divided into 3 categories and should be reported as brisk, non-
brisk and absent. Although the presence of host inflammatory response is generally associated
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with a better prognosis in melanoma, there are also studies reporting that no significant
correlation between lymphocytic infiltration and prognosis [119].
6.8.6. Histological subtype
There is no survival difference among three histological subtypes (superficial spreading,
nodular and acral lentiginous) when these are corrected for thickness. But lentigo malign
melanoma, particularly in woman, has been reported to have a better prognosis, independent
of thickness [51].
6.8.7. Regression
Regression is caused by the interaction between melanoma cells and host immune system.
Tumor tissue replaced with degenerative melanoma cells, melanophages, lymphocytic
proliferation, haphazard fibrosis and telangiectasias. Complete regression is characterized by
total absence of malignant melanoma cells in both dermis and epidermis. The correlation
between regression and prognosis is still controversial [119, 134].
6.8.8. Vascular invasion
Tumor cells may invade the vessel lumen. It correlates with the development of in-transit
metastases, when the presence of blood vessel and lymphatic invasion should be reported.
Vascular invasion is associated with poor prognosis and decreased survival in thick cutaneous
malignant melanomas [109, 119]. Angiogenesis is a distinct histological prognostic indicator
that is defined as the increasing development of new blood vessels at the base of the tumor
mass. Increasing angiogenesis is associated with thick tumors, surface ulceration, relapse and
tumor related death [114].
6.9. Immunohistochemistry of melanoma
Immunohistochemical staining is often used for differentiate melanomas from tumors that
they mimic in conventionally stained sections [139].
S-100 is a commonly used sensitive marker for melanoma. But its positivity appears some
tumors such as nerve sheath and granular cell tumors and myoepitheliomas. Although its
sensitivity is 97-100%, its specificity for melanocytic lesions is limited. The specificity of S-100
is ranged from 75% to 87%. S-100 A6 is one of the subtypes of S-100 protein, expressed in both
benign and malignant melanocytic lesions. S-100 A6 has been reported that it is expressed in
approximately 62-100% of metastatic and primary melanomas [140, 141].
HMB-45 is an antibody formed against the cytoplasmic premelanosomal glycoprotein gp100
while  its  sensitivity  is  lower  than S-100,  its  specificity  is  greater.  HMB-45  expression is
maximal  (77-100%)  in  primary melanomas.  This  rate  is  lower  (58-83%)  in  patients  with
metastatic lesions [139].
Melan-A, also known as melanoma antigen recognized by T cells-1 (MART-1), is an important
melanocytic marker. Sensitivity and specificity of Melan-A are similar to HMB-45 that ranged
Current Management of Malignant Melanoma: State of the Art
http://dx.doi.org/10.5772/55304
99
from 75-92% and 95-100%, respectively. It is less positive in lesions with metastatic melanomas
than primary melanoma [139].
MIB-1, also known as Ki-67, is a proliferation marker that is expressed by proliferating cells.
It provides guidance about presence or absence of “maturation”. MIB-1 has an important role
in distinguishing between melanocytic nevi and melanoma. While less than 5% of nuclei is
positive in melanocytic nevi, this ratio is greater (25% or more) in melanoma [114, 141].
Tyrosinase is an enzyme that plays a role in hydroxylation of tyrosine in the synthesis of
melanin. Its sensitivity for melanoma is slightly better than HMB-45 at 84-94%. The sensitivity
is reduced in advanced diseases and metastatic lesions (79-93%). The specificity is very high
for melanoma (97-100%) [139].
Microphthalmic transcription factor (MITF) is expressed in most benign melanocytic nevi and
melanomas. Nuclear staining occurs with MITF unlike cytoplasmic markers. MITF expression
has been reported in 81-100% of melanomas [51, 113].
There are also numerous immunohistochemical markers such as epithelial markers (keratin,
EMA, CEA), histiocytic markers (eg. CD68, Mac 378, alpha-1 antitrypsin), Bcl-2, Cyclin D1,
p16, CD40, CD44, melanoma cell adhesion molecule (Mel-CAM) [114].
7. Treatment
7.1. Staging workup
Any lesion that is clinically suspicious for melanoma should ideally undergo an complete
elliptical excisional biopsy with narrow margins (such as 2 mm) [12]. Wide excisions should
be avoided for obtaining an accurate result of the subsequent sentinel lymph node biopsy, if
necessary. Examination of the entire pigmented lesion allows for the greatest chance of
accurate diagnosis and also for the measurement of Breslow thickness and the assessment of
other prognostic factors [142]. Although there is evidence that an incisional biopsy does not
adversely affect survival, this approach should be an exception and reserved for cases in which
the tumor is too large to be excised, or when it is not practical to perform an excision. If the
lesion is large or located on certain anatomical sites such as palm/sole, digit, face or ear, a full-
thickness incisional biopsy can be performed, reaching to the adipose tissue. This biopsy
should be obtained from the most elevated or darkest area of the lesion, although there is not
always a correlation between clinical appearance and the thickest part of the lesion. If initial
biospy confirms melanoma with subtotal excision and if there is significant amount of residual
lesion, a narrow margined re-excision should be immediately made, to evaluate if the patient
is a candidate for sentinel lymph node biopsy.
Although cutaneous melanoma is rare in children and young adults, the incidence is rising
annually in this population. Staging work up is almost similar, in children and adults [143].
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7.2. Evaluation for regional metastasis
7.2.1. Macroscopic metastases
First step should always be history taking and physical examination. A careful lymph node
examination of the whole body should be made, particulary the regions close to the site of the
primary lesion. Also because of the aberrant lymphatic drainage pathways to unexpected
nodal basins and to interval nodes between the primary site and expected regional nodal basin,
a search for clinically detectable nodal disease in unexpected locations is crucial. If there is a
palpable lymph node during physical examination, first a fine needle aspiration biopsy should
be performed to make a histological confirmation. If the result of the fine needle aspiration is
inconclusive, an excisional biospy can be made. For the detection small nodal metastases, best
noninvasive methods seem to be ultrasound imaging and positron emission tomography, with
sensitivity and specificity being lower than tissue diagnosis [144].
7.2.2. Microscopic metastases
Sentinel lymph node biopsy (SLNB) as elective lymph node dissection (ELND) does not offer
a survival advantage to melanoma patients, a new approach, SLNB has become the choice of
biopsy type. Morton developed sentinel node biopsy as a means of ensuring that the node
biopsied was the one most likely to be the first draining lymph node. This technique was widely
adopted although the first randomized clinical trial to evaluate it was only published in 2006.
In SLNB, lymphoscintigraphy is used to identify the lymphatic drainage pattern from the site
of the primary melanoma, by injecting radiolabelled colloid and/or blue dye at the site of the
primary melanoma [145]. The tracer/dye is concentrated in the sentinel node and is detected
using a hand-held gamma probe (neoprobe) and examination by naked eye for the blue stained
node. Sometimes there is more than one sentinel node and sometimes these sentinel nodes are
in different lymph node basins. The node is removed and subjected to pathological examina‐
tion using immunohistochemistry (S100 and HMB-45) The surgical technique must be learnt
and false-negative results are more common in trainees, so an experienced medical team is
vital. The pathological examination of the nodes is also a skilled procedure; naevus cells may
be seen, for example, in the subcapsular area of the node and must be distinguished from
melanoma cells. The likelihood of a positive SLNB result is correlated with Breslow thickness.
Use of SLNB to stage patients for trials of adjuvant therapies would appear reasonable but the
patient should be aware that the risk of positivity is low. In patients with melanoma of Breslow
thickness from 1.5 to 4.0 mm, the risk of positive SLNBs is significantly higher at 23% [146].
The value of SLNB in patients with tumours of Breslow thickness 4 mm or thicker is question‐
able (if the intent is therapeutic as well as being a staging tool) because the risk of haematog‐
enous spread is so high. At present SLNB is of proven staging value but of no established
therapeutic value. Its use in identifying patients for adjuvant therapies means that it will
continue to be used, but its role must be evaluated in the long term.
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7.3. Evaluation for distant metastasis
For the evaluation of distant metastases, a thorough examination of the neurologic, psychiatric,
musculoskeletal, skin, lymphatic, endocrine, cardiovascular, and respiratory systems is
necessary. Patients with newly diagnosed melanoma require a complete cutaneous and
physical examination with particular attention to lymphadenopathy and hepatomegaly, and
a baseline chest radiograph. If the latter examinations fail to detect any evidence of metastatic
disease and the patient has no other symptoms or signs, no further laboratory evaluation is
indicated. Current imaging technics like computed tomography, magnetic resonance imaging,
PET, chest X-ray and laboratory tests like LDH are not routinely indicated as their sensitivity
ans specificity are low. According to current guidelines, no additional work up is necessary in
stage 0 and 1A, optional chest X-ray may be performed in stage 1B and 2, optional chest X-ray
and LDH for stage 3 and chest X-ray and/or chest CT and LDH for stage 4 can be done [146].
7.4. Treatment of primary melanoma
The Standard treatment for primary cutaneous melanoma is wide local excision. The aim of
wide excision is to reach histopathologically confirmed tumor-free margins, as well as
preventing local recurrence. Recommended clinical margins around the residual lesion or
biopsy scar for melanoma in situ, non lentigo maligna pattern, is 0.5 to 1 cm; for melanoma <1
mm Breslow depth a 1-cm margin; for melanoma 1 to 2 mm a 1- to 2-cm margin as anatomically
possible; for melanoma ≥ 2 mm a 2-cm margin. lesion excision at special sites, such as the digits,
soles, ears, vagina or anus, also requires individual surgical and functional consideration. For
subungal melanoma, partial or complete amputation of the digit is the choice of treatment.
Lentigo maligna and lentigo maligna melanoma have high potential for sub-clinical peripheral
extension, as their clinical margins are usually poorly defined and obscured by background
photo-damage. For lentigo maligna melanoma, the probability of a macular invasive desmo‐
plastic component is increased. Thus, standard surgical safety margins recommended, are
often insufficient for these two subtypes [12, 51].
7.5. Treatment of regional metastasis
7.5.1. Macrometastatic nodal disease
One of the main causes of melanoma-related morbidity with an important negative effect on
quality of life is the poor control of the nodal disease. Therefore, current standard of therapy
for microscopic or macroscopic melanoma in lymph nodes is complete dissection of the node
in the involved regional basin. According to the current guidelines, adequate lymphadenec‐
tomy is described as at least 10 nodes in the groin region, 15 lymph nodes in the axillary region
and 15 lymph nodes in the neck area. There are also some complications, leading to significant
morbidity, of the lymph node dissection, like wound infection, delayed wound healing,
seroma, lymphedema and nerve damage. In the case of regional metastatic melanoma,
complete lymph node dissection is associated with long-term survival rates [87].
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7.5.2. Micrometastatic nodal disease
For micrometastatic disease, elective lymph node dissection was the procedure of choice,
historically. It is the dissection of regional lypmh nodes draining the site of a primary cutaneous
melanoma, with no clinically palpable lymph nodes or overt metastatic disease. With today’s
knowledge, according to multiple prospective randomized-controlled trials, survival rates of
the patients undergoing elective lymph node dissection were found to be no higher than other
patients. Thus there is no role for elective lypmh node dissection today, especially considering
its significant morbidity and the availability of sentinel lypmh node biopsy [144]. For the
identification of micrometastatic nodal disease, sentinel node biopsy is the tool of choice. The
only handicap of sentinel node biopsy is that, it can not be classified as therapeutic yet. If the
result of the sentinel lymph node biopsy returns as positive, always a complete lymph node
dissection should be performed. According to current trials of investigations, immediate
complete lymph node dissection has a higher survival rate than delayed dissection.
7.5.3. Adjuvant therapy
Adjuvant therapy is usually given after surgical resection of the primary lesion. It is preferred
in patients with increased relapse risk. When thickness of the primary lesion is higher than 4
mm or when there is nodal involvement, adjuvant therapy is necessary. Up to now, interferon-
α2b (IFN- α2b) is the only form of adjuvant therapy, which is approved by U.S. Food and Drug
Administration. It has been shown that interferon-α2b improves disease-free survival for stage
2B and 3 melanoma, and it also improves overall survival. Interferon-α2b is used in high doses.
There are two phases of treatment with interferon, first phase is induction phase. During
induction, 20 million units per square meter of body surface area per day, are given intrave‐
nously, 5 days a week, for 4 weeks. After this high dose period, during the maintenance period,
10 million units per square meter per day, given subcutaneously three times a week for 48
weeks. During or after interferon treatment, autoantibodies like antithyroid, anti-nuclear, anti-
DNA, anticardiolipin autoantibodies may appear in blood tests of the patients and some
autoimmune diseases may develop. Both autoantibody positivity and development of
autoimmune diseases are associated with increased survival in those patients. High dose
interferon treatment may cause flu-like symptoms, fatigue, malaise, fever, nausea and
headache, depression, elevated levels of transaminases and myelosupression [147].
Melanoma vaccines: Vaccines stimulate specific immune response against melanoma-
associated antigens. They can be of autologous, allogenic or peptide type and also immuno‐
logic adjuvants like bacille Calmette-Guérin or DETOX are added. Target of the vacines can
be autologous tumor cells, allogenic melanoma cells, or more specifically heat shock proteins
and T cell defined antigens glycoprotein 100, tyrosinase, MART-1. Up to now, none of the trials
showed increased survival for the patients using these vaccines but more research on this area
should be done.




For localized disease, limited to one extremity only, first choice of treatment should ideally be
surgical excision with clear margins if possible. But in case of multiple lesions, chance of
performing an ideal excision may be low, so in that case, isolated limb perfusion can be
considered. It is a simple and less invasive, yet more effective treatment. Main idea about
isolated limb perfusion is giving high doses of chemotherapeutic agents locally, to avoid
systemic toxicity, and obtain more therapeutic effect. The technique of this method involves
perfusing an isolated arm or leg, in a hyperthermic environment, with cytotoxic agents.
Conventinally chemotherapeutic agent used in this procedure is melphalan. Approximately
in half of the patients, complete disappearance of the lesion is observed. Although systemic
side effects of this method is fairly less, when compared to conventinal chemotherapy, local
side effects can be serious. Significant tissue damage due to high concentrations of cytotoxic
agent can be seen. Compartment syndrome is one of the most severe morbidities. Advanced
age and patients with serious co-morbidities are usually not preferred for this type of treat‐
ment. A new approach is isolated limb infusion, which is a less invasive method, for appliance
on patients with older age or worse general health conditions. Isolated limb infusion can be
done with melphalan and actinomycin D [51, 67].
7.6. Treatment of distant or disseminated metastasis
In case of stage 4 melanoma, with distant metastasis, mean survival is 6 to 8 months and there
is currently no effective systemic treatment, to increase survival rate. For this reason, main
treatment goal is the palliation of symptoms. For the patients with increased age and serious
comorbidities, observation and conservative treatment may also be the option of choice [146].
If there are symptomatic visceral metastasis, surgical excision to perform metastasectomy can
be tried. Also excision of skin metastasis or lymph node metastasis may improve the locore‐
gional control of the disease and may help to decrease morbidity.
In one case report [148], a 44-year-old Caucasian woman who underwent extensive surgical
resection of a melanoma on the right side of her scalp, came with a new metastasis, a large
nodule in her right cheek. The patient underwent two sessions of electrochemotherapy with
intravenous injections of bleomycin, as neoadjuvant treatment permitting conservative
surgery three months later. In this case, electrochemotherapy offers the option of more
conservative surgery and an improved cosmetic effect with complete local tumor control.
Although melanoma is known to be radiotherapy resistant, for brain metastasis, spinal cord
compression and painful bone metastasis, local radiation can be used.
7.7. Radiation therapy
Radiation therapy plays a role in the management of primary cutaneous melanoma in
definitive, adjuvant, and palliative settings. The role for radiation therapy in early stage
primary melanom is limited as the treatment is adequate excision. However desmoplastic
melanoma and those with neurotropism invasion are exceptions, due to frequent local
recurrence [149]. The greatest controversy regarding radiotherapy lies with its use in stage III
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disease, particularly as postoperative treatment after lymph node dissection. A recently
completed randomized trial confirmed the benefit of adjuvant radiotherapy in improvement
in nodal field control after nodal dissection for patients who are at moderate to high risk for
regional relapse [150].
For primary melanoma, adequate surgery is usually the best option for local control and cure.
Factors often considered indicative of the need for adjuvant radiation therapy include primary
site in the head and neck region, close or positive margins not amenable to further excision,
lymphatic space invasion, multiple recurrences, and desmoplastic neurotropic growth [149].
Apart from its use in an adjuvant setting, radiation therapy has been used as the definitive
treatment of primary melanomas, locally advanced acral lentiginous melanoma, and as a
substitute for wide excision after limited excision.
Radiation therapy has a well-established role in patients with metastatic melanoma. Symptoms
of pressure, mass effect, and bleeding from metastases in a variety of locations may benefit
from palliative radiation. The development of stereotactic techniques has improved the efficacy
of radiation for brain metastases. Expansion of this methodology to stereotactic body radiation
metastases has the potential to improve further palliation of unresectable metastases.
7.8. Systemic therapies
7.8.1. Chemotherapy
For systemic chemotherapy, first line chemotherapeutic agent is dacarbazine, an alkylating
agent. It is an U.S. Food and Drug Administration (FDA) approved chemotherapy drug for
metastatic melanoma. It is thought to be the most effective single agent therapy. Approxi‐
mately 10 to 20% of the patients response to treatment and the mean duration of response is 4
to 6 months. Dose of the treatment does not affect the response rate. Major side effects of
dacarbazine are nausea and vomiting. Temozolomide is also an alkylating agent. This
chemotherapeutic agent can also be used orally. Another advantage is that, temozolomide can
cross the blood-brain barrier. Thus for patients with central nervous system involvement,
temozolomide can be preferred. According to a randomized phase 3 study, its efficacy is equal
to dacarbazine. For metastatic melanoma to brain, a combination of temozolomide and
thalidomide, along with radiation, can be benefical. For dacarbazine, increased response rates
are reported, when combined with other cytotoxic agents like cisplatin, vinblastine, carmustine
or tamoxifen [144].
7.8.2. Immunotherapy
Among immunotherapeutic agents, interleukin 2 (IL-2) is the only agent, which has an
approval form FDA. Overall response rate of this agent is 16%, but a durable response rate is
5 to 8%. Approximately the time for the duration of response is 9 months. Of the 28% of the
patients with metastatic melanoma who responded to IL-2 treatment, no progression was
observed at a follow-up period of 62 months. Also patients who responded longer than 30
months, did not show any sign of relapse afterwards. On the other hand, there are some
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important side effects of IL-2 treatment. Most common side effect of IL-2 is hypotension. It can
also cause capillary leak syndrome, supraventricular tachycardia, transient renal insufficiency,
respiratory distress, increased susceptibility to infections. There are also newer investigations
about combining IL-2 with tumor-infiltrating lymphocytes and lymphokine activated killer
cells. These immunologically active cells are considered to be helpful in transferring and
adoptive immune force, to generate an antitumor effect.
In a case study [151], patient with cutaneous metastasis with significant comorbidities,
including advanced age, anticoagulation for a metallic valve, chronic anemia, macular
degeneration, and history of hematopoietic malignancy (high-grade lymphoma, Walden‐
strom macroglobulinemia) was treated with a novel method. 1% gentian violet was applied to
the wounds, and the patient was instructed to apply gentian violet and imiquimod to the base
of the lesions daily. This was accompanied by a brisk inflammatory response. At the time of
reexamination, 4 months after the procedure, no clinical recurrence was noted. This method
can be useful when surgery is not an option.
In another case [152], 82-year-old man who presented with rapidly progressing cutaneous
melanoma metastases, together with inguinal lymph nodes and bilateral pulmonary involve‐
ment, treated with topical immunotherapy with diphencyclopropenone (DPCP) in aqueous
cream weekly to elicit moderate contact hypersensitivity. Larger lesions were also treated with
intralesional 5-fluorouracil (50 mg/mL). One month later, cutaneous metastases began to
regress, and during the following 4 months his inguinal lymphadenopathy and pulmonary
lesions disappeared. He remains clinically disease free 18 months after his metastases began
to regress. This can show the potential for some patients to overcome even widespread and
extensive disease, presumably via immune-mediated regression, and raises the possibility that
topical immunotherapy may play a role even in patients with bulky disease.
7.8.3. Biochemotherapy
Biochemotherapy alone has not shown any increase in overall survival rate, but when
compared to other systemic chemotherapeutic agents like dacarbazine, or interferon, vaccines,
IL-2, it can show better results.
7.8.4. Novel therapies
About the etiopathology of intrinsic resistance of malignant melanoma to chemotherapy, the
anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) is found to play an important role. A new
antisense Bcl-2 oligonucleotide, Oblimersen, is targeting Bcl-2 messenger RNA selectively and
this leads to the degradation of the Bcl-1, thus decreasing the levels of Bcl-2 in the body.
Oblimersen can also be used in combination with conventional systemic chemotherapeutic
agents, like dacarbazine.
Also in two-thirds of melanomas, there is a mutation in B-raf gene. A RAF inhibitor, Sorafenib,
inhibits both B-raf and C-raf, and also used orally. Since the evaluation of sorafenib, a new
generation of BRAF inhibitors has been developed. These drugs show higher potency against
mutated BRAF and have fewer off-target effects; the list of those currently under preclinical
Highlights in Skin Cancer106
investigation includes SB590885, dabrafenib (GSK2118436), AZ628, XL281, GDC-0879, and
vemurafenib (RG704, PLX4032/4720) [153]. PLX4032 (and its analogue PLX4720) are adenosine
triphosphate (ATP)-competitive RAF inhibitors (wild-type BRAF 50% inhibitory concentration
[IC50]-100 nmol/L, mutated BRAF IC50-31 nmol/L) that selectively inhibit growth in melano‐
ma cell lines harboring the BRAF V600E mutation in both in vitro and in vivo mouse xenograft
models [154].
Much of the foundation for the development of these treatments is the realisation that
melanoma growth and progression is driven by somatic activating mutations in signalling
molecules such as BRAF, KIT, NRAS and GNAQ/GNA11 [147]. Active drugs targeting BRAF
and KIT are available and and the anti-CTLA4 antibody ipilimumab has shown an overall
survival benefit and the possibility of prolonged disease control in the metastatic setting.
Although there are many phase III trials in progress, about treatment of metastatic melanoma,
up to now, no curative adjuvant or systemic therapies have been approved for stage 4
metastatic melanoma. Among these treatments some may have serious side effects. According
to one study [7], patients with metastatic melanoma are treated with the selective BRAF
inhibitor, dabrafenib. Keratinocyte proliferation is characteristic of BRAF inhibitor induced
cutaneous toxicities, and the spectrum of lesions ranges from benign seborrhoreic keratoses,
Grover’s disease and plantar hyperkeratosis through to verrucal keratoses of undetermined
prognosis and malignant well differentiated SCCs.
In the future of metastatic melanoma treatment, molecular profiling of patient tumors will play
an important role in the part of therapy selection for medical oncologists. Recent preclinical
studies shows that inhibitors of BRAF paradoxically activate MAPK signaling in tumors that
lack activating BRAF mutations [153]. Reports from six independent groups have shown that
BRAF inhibition activates MAPK in cell lines with NRAS and KRAS mutations, as well as those
cell lines where the MAPK pathway is activated through other oncogenes such as HER2.
Studies showed that although vemurafenib and other BRAF inhibitors were able to profoundly
inhibit the activity of BRAF V600E-containing complexes in melanoma cells, they instead
promoted the activity of CRAF-CRAF dimers in cells with RAS mutations, leading in turn to
MEK activation. There is also evidence that PLX4032 increases the invasive potential of NRAS-
mutated melanoma cells through the activation of ERK and FAK signaling. Additional studies
demonstrated that BRAF inhibitors may even contribute to the progression of NRAS-mutated
melanomas in part by suppressing apoptosis through the modulation of Mcl-1 expression.
According to one study [155], data of 97 patients with melanoma show substantial clinical
activity of trametinib, MEK inhibitor. Differences in response rates during this treatment,
according to mutations indicate the importance of mutational analyses.
These studies are extremely important for approaching the development of new cancer
therapies as they indicate that simple empiric evaluation of novel cancer therapeutics in
patients could be associated with adverse outcomes. Instead they affirm the approach of
rationally developing therapies in cancer patients based on strong preclinical data and
individual patient molecular profiling.




Melanoma is considered as a rather “immunogenic” tumor. One can understand it by the
spontaneous  immune-mediated  regression  of  primary  tumors,  association  between
infiltrating T lymphocytes and improved survival,  response to nonspecific immunothera‐
py agents,  including interferon-alpha,  IL-2,  and ipilimumab and identification of  tumor-
associated  melanoma  antigens  and  human  leukocyte  antigen  (HLA)-restricted  epitopes
within these anti- gens [156].
A variety of strategies, including peptide and protein vaccines, recombinant DNA and viral
vectors, and the use of autologous and allogeneic whole cell vaccines, have been tested in
patients.  Although many studies have not had significant clinical benefit,  there are some
important data that have emerged from these clinical trials. There also have been at least
two randomized phase III  vaccine trials  that  have shown a clinical  benefit  in melanoma
[157].
There has been considerable interest in the identification of patient-specific and tumor-specific
biomarkers that may predict therapeutic response and clinical outcomes. These studies would
help select patients more likely to respond to a particular vaccine approach and might identify
new strategies for improving the potency of individual vaccines so that more patients might
benefit from immunotherapy.
8. Prognosis
Malignant melanoma is the most fatal type of the skin cancers. The best survival rates of
melanoma arise if it is detected at the early stages, this is generally when the size of the tumours
is small and treatable. After detection the prognosis of the melanoma can be determined by
assessing a number of histopathological (morphological) factors such as the thickness of
lesions, levels of invasion, presence of ulceration and the number of metastatic lymph nodes
involved. Clinical prognostic factors such as age, sex, anatomical location of the tumour can
also be used to determine the possible progression of the cancer and the likely survival rates
of the patient. The thickness of the tumor is the dominant prognostic factor in determining risk
of metastasis and prognosis for cutaneous melanoma [158, 159]. The American Joint Commit‐
tee on Cancer (AJCC) tumor node metastasis committee has approved a new melanoma
staging system, which was implemented in 2009 [160]. The prognostic factors included in AJCC
staging system are tumor thickness, ulceration, level of invasion (Clark's level) and mitotic rate
[160, 161].
In the AJCC staging system, tumor thickness is the most powerful independent prognostic
factor for patients with cutaneous melanoma. Melanoma thickness is measured from the
granular layer of the epidermis to the greatest depth of tumor invasion, this was originally
described by Breslow in 1970. Now it is correlated with a thickness of ≤1 mm (T1), 1.01 to 2 mm
(T2), 2.01 to 4 mm (T3), or ≥4 mm (T4) [159]. In it, invasive tumor thickness is used to predict
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5-year survival. In general, the higher the Breslow thickness, the worse the prognosis (Table
3) [161,162].
Breslow thickness 5-year survival
≤1 mm (T1) 95% to 100%
1.01 to 2 mm (T2) 80% to 96%
2.01 to 4 mm (T3) 60% to 75%
>4 mm (T4) 37% to 50%
Table 3. The relation of Breslow thickness and prognosis
The depth of the tumor is most accurately measured by evaluating the entire tumor via an
excisional biopsy. Determination from specimens obtained using other biopsy techniques,
such as a wedge or punch biopsy, is less accurate. Tumor depth cannot be calculated from a
shave biopsy that only contains a portion of the tumor because it leads to an underestimation
of its thickness. Excisional biopsy should extend down to the subcutaneous fat tissue [163].
Clark level of invasion is a method for determining the prognosis (outlook) with melanoma.
This method was devised by the pathologist Wallace Clark and measured the depth of pene‐
tration of a melanoma into the skin according to anatomic layer. There are five Clark levels of
invasion (Table 1).
The Clark levels provide a system to relate the degree of penetration of melanoma into the skin
to the 5-year survival rate after surgical removal of the melanoma [158, 161, 164].
Ulceration is the second most powerful factor for poor prognosis. The presence of ulcerations
on the surface of the tumour causes a reduction in the survival rate. Ulcerations appear when
an intact epidermis is not present around the tumour and is usually a result of an aggressive
tumour. The presence of ulceration in tumours less than 1mm, causes a reduction in survival
rate by 4% compared to non-ulcerated tumour. Survival rates can be reduced by up to 22% if
the tumour thickness is greater than 4mm.This therefore, indicates that tumour thickness and
ulceration have strong relationship with survival rates and so the prognosis of thin non-
ulcerated melanoma is excellent [51].
Current studies have shown that tumor mitotic rate is a powerful independent prognos‐
tic  factor.  But  the prognostic  importance of  mitotic  rate  in melanoma recurrences is  not
known. A high mitotic rate also correlates with a greater likelihood of having a positive
sentinel lymph node biopsy. The mitotic rate is measured by simply examining the excised
tumor with a microscope and manually counting the number of cells exhibiting mitosis, an
easily identifiable characteristic of dividing cells. Most often, the mitotic rate is reported as
one of three categories :
• less than 1 per square millimeter
• 1 to 4 per square millimeter
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• greater than 4 per square millimeter
The higher the mitotic count, the more likely the tumor is to have metastasized. The logic is
that the more cells are dividing, the more likely they will invade the blood or lymphatic systems
and thus spread around the body. Research has shown that the odds of survival for patients
with stage I melanoma and a mitotic rate of 0 per square millimeter is twelve times better than
that of patients with a mitotic rate of greater than 6 per square millimeter. Also, only 4% of
lesions with low mitotic rate recur compared to 24% of those with a high mitotic rate. Mitotic
rate can also help to predict that your sentinel lymph node biopsy will be positive or not.
Although mitotic rate has no role in the current staging system for melanoma, research has
demonstrated that it is a more important prognostic factor than ulceration, which does have
an important role in staging. The American Academy of Dermatology argues that mitotic rate
should be optional in biopsy reports or not. On the other hand, the National Comprehensive
Cancer Center recommends that mitotic rate should be reported for all lesions in stage I to II
patients. Still other experts argue that measuring the mitotic rate should only be done in large
academic medical centers for future research purposes. Increasing mitotic rate is related with
a decreasing survival [165, 166].
Tumor-infiltrating lymphocytes (TILs) describe the patient's immune response to the mela‐
noma. One marker used to determine immune activity in melanoma is the presence in sentinel
lymph node biopsy samples, which has been variably associated with a favorable prognosis.
Some investigators assessed whether the presence of tumor-infiltrating lymphocytes was an
independent predictor of sentinel lymph node biopsy status and survival or not [167, 168].
Microscopic satellites are defined as dermal or subcutaneous nodules. Microscopic satellites
in primary melanomas are considered to be localized micrometastases developing in close
proximity to the main tumoral portion of melanomas and show bad prognosis. In particular,
the presence of angiotropism predicts the detection of microscopic satellites, and microscopic
satellites probably develop as a result of extravascular migration. Consequently the linkage
between microscopic satellites and angiotropism provides additional support for extravascu‐
lar migratory metastasis as a mechanism of melanoma metastasis. Finally, ongoing investiga‐
tions to develop a more specific biomarker for angiotropism and extravascular migratory
metastasis are essential for the more precise recognition of extravascular migratory metastases
and the explaining of its biological and prognostic significance. This pericytic angiotropism of
melanoma cells, without any sign of intravasation, suggests that melanoma cells may migrate
along the external surface of vessels, a mechanism we have termed extravascular migratory
metastasis (EVMM), as distinct from intravascular dissemination [51, 169].
Common cell types are epithelioid and spindle cells, although mixed cells may also be seen.
Generally, spindle cells are associated with better prognosis than other cell types.
The incidence of malignant melanoma appears to be increasing at an alarming rate throughout
the world over the past 35-40 years and continues to increase in the USA, Canada, Asia,
Australia, and Europe. The behavior of head and neck melanoma is aggressive, and it has an
overall poorer prognosis than that of other skin sites. Correlations between different factors
were found, e.g. tumour localisation predominating on the back in males and on the legs in
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female. In one study, 11.734 patients were analyzed, 49.3% were male. Between 1978 and 1992,
most of the newly registered melanoma patients were female, but after 1992 there was a higher
incidence of male patients. Men exhibited a disadvantaged distribution for almost all prog‐
nostic indicators being significantly older at diagnosis, having thicker melanomas, and having
more melanomas localized on the trunk or head and neck. In analyses of histological subtypes,
females had significantly more lentigo maligna melanomas and acral lentiginous melanomas,
but the incidence of superficial spreading melanoma and nodular melanoma did not differ
across gender. Males more often presented with lymph node metastases or distant metastases
at the time of diagnosis than did females (5.2 vs. 3.0% and 1.7 vs. 1.1%, respectively). Whereas
overall disease progression, lymph node metastasis, and distant metastasis occurred signifi‐
cantly more often in males than in females, local recurrence and in-transit/satellite metastases
were equally common [170-172].
If we summarize, prognostic factors include tumor thickness (mm), levels of invasion, presence
of ulceration, increased mitotic rate. Prognosis is better if there happens to be tumor-infiltrating
lymphocytes around the lesion. There is stil controversy going on about regression. Some
studies have shown an adverse outcome while others no effect, or a favorable outcome.
Presence of microscopic satellites shows bad prognosis and also angiotropism is a bad
prognostic marker. Vascular/lymphatic invasion, although seen very rarely, indicates unfav‐
orable prognosis. Tumor cell type also has an effect on prognosis. Better prognosis with spindle
cells versus other cell types. Prognosis worsens with increasing age and women have better
prognosis than men. Extremity lesions have better prognosis than axial lesions (trunk, head
and neck, palms and soles) [12, 173].
9. Patient education
Melanoma is the most dangerous form of skin cancer [174]. The incidence of melanoma is
increasing worldwide, more than other cancers. The clinicians has the greatest impact on
reducing these cases. They educate patients about early detection, treatment and prevention
methods [175]. UV light is the most important risk factor for melanoma development. The risk
of developing melanom may be reduced by protecting from UV light exposure. We must
educate others as to the importance of sun protection [174]. Patients should be educated to
avoid intense intermittent sun exposure and minimize cumulative sun exposure [176].
Avoiding overexposure to direct sunlight during the peak daylight hours, wearing protective
clothing, and applying sunscreen are the ways to protect the skin [177].
Clinicians must educate patients as to the importance of using sunscreens that protects against
both UVA and UVB light and with an SPF 30 or greater [174, 175]. It is important to emphasize
the correct application of the recommended amount of sunscreen and the need for reapplica‐
tion of sunscreen [176]. Sunscreen should be applied to exposed dry skin 15 to 30 minutes
before sun exposure. The standard amount of sunscreen used in SPF testing is 2 mg/cm2.
Sunscreen should be reapplied every 2 hours or after swimming or heavy perspiration; many
water-resistant sunscreens lose effectiveness after 40 minutes in the water [177]. Clinicians
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recommend patients sun protective clothing such as sunglasses, hats or long sleeve clothing.
Patients should be avoided direct exposure to the sunlight between 9 AM - 3 PM and tanning
beds [174]. There is great concern in regard to the total amount of sun exposure during infancy
and early childhood [175]. The importance of sun protection in childhood should be empha‐
sized [176].
Self-examination of skin by informed patients in terms of suspicious nevi is an important
contributory factor in the early diagnosis of melanoma [178].
Skin self examination has the potential to significantly reduce melanoma mortality. One
retrospective study concluded that skin self examination has the potential to reduce melanoma
mortality by 63% [179]. One study found that 44% of diagnosed recurrent melanoma was
initially detected by patients based on symptoms that raised suspicion of metastasis [180]. For
this reason, patients shoul be educated about the skin self examination. Patient education in
skin self examination includes information on the warning signs of melanoma. Also it includes
directions on how to perform a thorough whole-body skin examination [176]. Patients at higher
risk should carefully examine their own skin monthly and also be frequently examined by
dermatologists professionally [174].
Older individuals are both more likely to acquire and to die from cutaneous melanoma; thus,
elderly people should be a primary target for secondary melanoma prevention. We must be
careful for the early detection and patient routine screening. Also secondary melanoma
prevention should be focused on targeted education to older men and their spouses for early
detection and reduction of mortality in this extremely high-risk group [181].
Following the diagnosis of cutaneous melanoma, all patients should be educated on the risks
of developing a second primary melanoma. In addition, counselling on the common clinical
characteristics of cutaneous melanomas and instruction on how to perform a skin self exami‐
nation should be provided. In the event of the development of new pigmented lesions or
changes in preexisting pigmented lesions, patients should be advised to seek medical attention.
In addition, appropriate lifelong follow-up surveillance is critical for the detection of thinner,
more curable melanomas [182].
Most of the studies suggested that many cancer patients want to get detailed information
about  their  disease,  treatment  options  and prognosis  of  the  disease.  The  most  common
complaint of these patients is not to told what is wrong with them, during the treatment.
Cancer care professionals are beginning to recognize that patients’ information needs and
preferences [183].
With growing evidence that well-informed patients are more satisfied with their care and do
better clinically. Efforts are needed to improve the information provision to melanoma
patients. Exploration of the patients’ personal information needs must lead to a more patient-
tailored approach of informing melanoma patients. A good opportunity would be the
implementation of a survivorship care plan, which aims at providing a cancer survivor with
a summary of their course of treatment, management of late effects, and strategies for health
promotion [184].
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The importance of malignant melanoma as a potentially fatal skin cancer among Caucasian
populations worldwide has received critical attention in recent years. As compared to other
life-threatening malignancies such as breast or prostate carcinoma, melanoma may be
diagnosed by simple inspection of the skin surface with 80 to 90% accuracy. Sun avoidance,
regular self-examination are important measures that can easily be applied. Future investiga‐
tions is needed to establish whether education and modification of behavior such as reduced
sun exposure and various methodologies of skin examination have a significant impact in
reducing mortality from melanoma.
Author details
Zekayi Kutlubay*, Burhan Engin, Server Serdaroğlu and Yalçın Tüzün
*Address all correspondence to: zekayikutlubay@hotmail.com
İstanbul University, Cerrahpaşa Medical Faculty, Department of Dermatology, İstanbul,
Turkey
References
[1] Chin L, Merlino G, DePinho RA. Malignant melanoma: modern black plague and ge‐
netic black box. Genes Dev. 1998; 12: 3467-3481.
[2] Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant
melanoma. Oncogene 2003; 22: 3099–3112.
[3] Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of
cutaneous malignant melanoma. Br J Dermatol 2004; 150: 179–185.
[4] Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27: 3–9.
[5] Ko JM, Velez NF, Tsao H. Pathways to Melanoma. Semin Cutan Med Surg 2010; 29:
210-217.
[6] Kanavy HE, Gerstenblith MR. Ultraviolet Radiation and Melanoma. Semin Cutan
Med Surg 2011; 30: 222-228.
[7] Paek SC, Sober AJ, Tsao H, Mihm MC, Johnson TM. Cutaneous Melanoma In: Wolff
K, Goldsmith LA, Katz SI, Gilchrest B, Paller AS, Leffell DJ. (eds): Fitzpatrick’s Der‐
matology in General Medicine, 7th ed. New York: Mc Graw Hill Companies, 2008;
1134-1157.
[8] Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365: 687–
701.
[9] De Vries E, Bray FI, Coebergh JW, Parkin DM. Changing Epidemiology of Malignant
Cutaneous Melanoma in Europe 1953–1997: Rising Trends in Incidence and Mortali‐
Current Management of Malignant Melanoma: State of the Art
http://dx.doi.org/10.5772/55304
113
ty but Recent Stabilizations in Western Europe and Decreases in Scandinavia. Int. J.
Cancer 2003; 107; 119–126.
[10] van den Hurk K, Niessen HE, Veeck J, Van den Oord JJ, Van Steensel MA, Hausen
AZ, van Engeland M, Winnepenninckx VJ. Genetics and epigenetics of cutaneous
malignant melanoma: A concert out of tune. Biochimica et Biophysica Acta 2012;
1826: 89–102.
[11] De Vries E, Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer
2004; 40: 2355–2366.
[12] Bishop J.A.N. Lentigos, Melanocytic Naevi and Melanoma In: Burns T, Breathnach S,
Cox N, Griffiths C (eds): Rook’s Textbook of Dermatology, 8th ed. Oxford, Blackwell
publishing, 2010; 54.32-54.56.
[13] Dennis LK, Vanbeek MJ, Beane Freeman LE, et al: Sunburns and risk of cutaneous
melanoma: Does age matter? A comprehensive meta-analysis. Ann Epidemiol 2008;
18: 614-627.
[14] Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS
2007; 115: 1161–1176.
[15] Cust AE, Armstrong BK, Goumas C, et al: Sunbed use during adolescence and early
adulthood is associated with increased risk of early-onset melanoma. Int. J. Cancer
2011; 128: 2425–2435.
[16] Loria D, Matos E. Risk factors for cutaneous melanoma: a case control study in Ar‐
gentina. Int J Dermatol 2001; 40: 108-114.
[17] Ashton-Prolla P, Bakos L, Junqueira G, et al: Clinical and Molecular Characterization
of Patients at Risk for Hereditary Melanoma in Southern Brazil. J Invest Dermatol
2008; 128: 421–425.
[18] Rebecca VW, Sondak VK, Smalleya KS. A brief history of melanoma: from mummies
to mutations. Melanoma Research 2012; 22: 114–122.
[19] Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF Mutations
Arise Early during Melanoma Pathogenesis and Are Preserved throughout Tumor
Progression. Clin Cancer Res 2003; 9: 6483-6488.
[20] Pons M, Quintanilla M. Molecular biology of malignant melanoma and other cutane‐
ous tumors. Clin Transl Oncol 2006; 8: 466-74.
[21] Curtin JA, Fridlyand J, Kageshita T. Distinct Sets of Genetic Alterations in Melanoma.
N Engl J Med 2005; 353: 2135-47.
[22] Demierre MF, Sondak VK. Cutaneous melanoma: pathogenesis and rationale for che‐
moprevention. Crit Rev Oncol Hematol 2005; 53: 225–239.
[23] Nikolaou V, Kang X, Stratigos A et al. Comprehensive mutational analysis of
CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Br J Dermatol.
2011; 165: 1219-22.
Highlights in Skin Cancer114
[24] Romano C, Schepis C. PTEN gene: a model for genetic diseases in dermatology. Sci‐
entificWorldJournal. 2012; 2012: 252457.
[25] Kim M. Cooperative interactions of PTEN deficiency and RAS activation in melano‐
ma metastasis. Small GTPases. 2010; 1: 161-164.
[26] Wang S, Setlow R, Berwick M, Polsky D, Marghoob A, Kopf A, Bart R. "Ultraviolet A
and melanoma: a review". J Am Acad Dermatol 2001; 44 (5): 837–846.
[27] Geller AC, Miller DR, Annas GD, Demierre MF, Gilchrest BA, Koh HK. Melanoma
incidence and mortality among US whites, 1969-1999. JAMA. 2002; 288: 1719-20.
[28] Wei Q. Repair of UV-induced DNA damage and Melanoma Risk. From melanocytes
to melanoma. Eds. Hearing Vj, Leong Spl. Totowa: Humana Pres Inc. 2006: 441-453.
[29] Whiteman D.C, Whiteman C.A, Green, A.C. Childhood sun exposure as a risk factor
for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control
2001; 12: 69–82.
[30] Khlat M, Vail A, Parkin M, Green A. "Mortality from melanoma in migrants to Aus‐
tralia: variation by age at arrival and duration of stay". Am J Epidemiol 1992; 135
(10): 1103–1113.
[31] Hausauer AK, Swetter SM, Cockburn MG, Clarke CA. Increases in melanoma among
adolescent girls and young women in California: trends by socioeconomic status and
UV radiation exposure. Arch Dermatol. 2011; 147: 783-9.
[32] Wolf P, Donawho C K, Kripke M L. "Effect of Sunscreens on UV radiation-induced
enhancements of melanoma in mice". J. Nat. Cancer. Inst. 1994; 86 (2): 99–105.
[33] Bliss J, Ford D, Swerdlow A, Armstrong B, Cristofolini M, Elwood J, Green A, Holly
E, Mack T, MacKie R. "Risk of cutaneous melanoma associated with pigmentation
characteristics and freckling: systematic overview of 10 case-control studies. The In‐
ternational Melanoma Analysis Group". Int J Cancer 1995; 62 (4): 367–376.
[34] Miller A, Mihm M. "Melanoma". N Engl J Med. 2006; 355 (1): 51–65.
[35] Rhodes A, Weinstock M, Fitzpatrick T, Mihm M, Sober A. "Risk factors for cutaneous
melanoma. A practical method of recognizing predisposed individuals". JAMA 1987;
258 (21): 3146–3154.
[36] Esther de Vries, Freddie I Bray, Jan Willem W Coebergh, Donald M Parkin. Chang‐
ing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising
trends in incidence and mortality but recent stabilizations in western Europe and de‐
creases in Scandinavia. International Journal of Cancer. 2003; 107(1): 119-126.
[37] Reed KB, Brewer JD, Lohse CM, Bringe KE, Pruitt CN, Gibson LE. Increasing inci‐
dence of melanoma among young adults: an epidemiological study in Olmsted
County, Minnesota. Mayo Clin Proc. 2012; 87(4): 328-834.
Current Management of Malignant Melanoma: State of the Art
http://dx.doi.org/10.5772/55304
115
[38] Cockburn M, Swetter SM, Peng D, Keegan TH, Deapen D, Clarke CA. Melanoma un‐
derreporting: why does it happen, how big is the problem, and how do we fix it? J
Am Acad Dermatol. 2008; 59: 1081-5.
[39] Swetter SM. Cutaneous Melanoma. Elston DM (Eds). http://emedi‐
cine.medscape.com/article/1100753-overview#a0199 (accessed 5 September 2012).
[40] Karagas MR, Zens MS, Stukel TA, et al. Pregnancy history and incidence of melano‐
ma in women: a pooled analysis. Cancer Causes Control 2006; 17: 11-19.
[41] MacKie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2
cutaneous melanoma. Br J Cancer 2004; 90: 770-772.
[42] Pukkala E, Aspholm R, Auvinen A, et al Incidence of cancer among Nordic airline
pilots over five decades: occupational cohort study. BMJ 2002; 325: 567.
[43] Bastiaannet E, Homan-van der Heide JJ, Ploeg RJ, Hoekstra HJ No increase of mela‐
noma after kidney transplantation in the northern part of The Netherlands. Melano‐
ma Res. 2007; 17: 349-353.
[44] Lindelof B, Sigurgeirsson B, Gabel H, Stern RS Incidence of skin cancer in 5356 pa‐
tients following organ transplantation. Br J Dermatol 2000; 143: 513-519.
[45] Kitchener S. Epidemiology of Melanoma Color Atlas of Melanocytic Lesions of the
Skin. Ed. Soyer HP, Argenziano G, Hofmann-Wellenhof R, Berlin Heideberg: Spring‐
er-Veriag; 2007; 185-195.
[46] Green AC, O’Rourke MG. Cutaneous malignant melanoma in association with other
skin cancers. J. Natl. Cancer Inst. 1985; 74: 977–980.
[47] Berwick M, Wiggins C, The current epidemiology of cutaneous malignant melano‐
ma. Journal Article Frontiers in Bioscience 2006; 11: 1244-1254.
[48] Purdue MP, Freeman LE, Anderson WF, Tucker MA. Recent trends in incidence of
cutaneous melanoma among US Caucasian young adults. J Invest Dermatol. 2008;
128: 2905-8.
[49] Lea CS, Holly EA, Hartge P, et al. Reproductive risk factors for cutaneous melanoma
in women: a case-control study. Am J. Epidemiol 2007; 165: 505-513.
[50] Driscoll MS, Grin-Jorgensen CM, Grant-Kels JM. Does pregnancy influence the prog‐
nosis of malignant melanoma?. J Am Acad Dermatol. 1993; 29(4): 619-30.
[51] Bailey EC, Sober AJ, Tsao H, Mihm MC, Johnson TM. Cutaneous melanoma. In:
Goldsmith LA, Katz SI, Barbara AG, Paller AS, Leffell DJ, Wolff K. (Eds). Fitzpa‐
trick’s Dermatology in General Medicine 8th Edition. New York, Mc Graw Hill Medi‐
cal, 2012; 1416-1444.
[52] Swetter SM, Boldrick JC, Jung SY, Egbert BM, Harvell JD. Increasing incidence of len‐
tigo maligna melanoma subtypes: northern California and national trends 1990-2000.
J Invest Dermatol. 2005; 125(4): 685-91.
Highlights in Skin Cancer116
[53] Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total
accumulated exposure to the sun: an analysis separating histogenetic types. J Natl
Cancer Inst. Jul 1984; 73: 75-82.
[54] Liu V, Mihm MC. Pathology of malignant melanoma. Surg Clin North Am. 2003;
83(1): 31-60.
[55] Clark GS, Pappas-Politis EC, Cherpelis BS, Messina JL, Möller MG, Cruse CW, Glass
LF. Surgical management of melanoma in situ on chronically sun-damaged skin.
Cancer Control. 2008; 15(3): 216-24.
[56] Gross EA, Andersen WK, Rogers GS. Mohs micrographic excision of lentigo maligna
using Mel-5 for margin control. Arch Dermatol. 1999; 135(1): 15-7.
[57] King DM. Imaging of metastatic melanoma. Cancer Imaging 2006; 6: 204–208.
[58] McKenna JK, Florell SR, Goldman GD, Bowen GM. Lentigo maligna/lentigo maligna
melanoma: current state of diagnosis and treatment. Dermatol Surg. 2006; 32(4):
493-504.
[59] Gürer MA, Adışen E. Kutanöz melanoma. In: Dermatoloji. Tüzün Y, Gürer M, Ser‐
daroğlu S, Oğuz O, Aksungur V. (eds). 3rd Edition. İstanbul, Nobel Tıp Kitabevleri,
2008; 1791-1823. (Turkish)
[60] Langholz B, Richardson J, Rappaport E, Waisman J, Cockburn M, Mack T. Skin char‐
acteristics and risk of superfcial spreading and nodular melanoma. Cancer Causes
and Control, 2000; 11: 741-750.
[61] Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published stud‐
ies. Int J Cancer. 1997; 73(2): 198-203.
[62] Interactive Medical Media. Dermatology lectures on line. Dermoscopy. http://
www.dermlectures.com
[63] Chamberlain A, Ng J. Cutaneous melanoma--atypical variants and presentations.
Aust Fam Physician. 2009; 38(7): 476-82.
[64] Lang PG. Current concepts in the management of patients with melanoma. Am J Clin
Dermatol. 2002; 3(6): 401-26.
[65] Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites,
Hispanics, Asians, and blacks: an analysis of california cancer registry data,1988-93.
Cancer Causes Control. 1997; 8(2): 246-52.
[66] Byrd KM, Wilson DC, Hoyler SS, Peck GL. Advanced presentation of melanoma in
African Americans. J Am Acad Dermatol. 2004; 50(1) :21-4; discussion 142-3.
[67] Nestle FO, Halpern AC. Melanoma. In: Dermatology. Volume 2. Eds. Bolognia JL,
Jorizzo JL, Rapini RP. 2nd Edition. Spain. Mosby, 2008; 1745-1771.
[68] Roesch A, Volkenandt M. Melanoma. In: Braun-Falco’s Dermatology. Burgdorf
WHC, Plewig G, Wolff HH, Landthaler M. eds. 3rd Edition. Heidelberg, Springer;
2009; 1416-1432.
Current Management of Malignant Melanoma: State of the Art
http://dx.doi.org/10.5772/55304
117
[69] Piliang MP. Acral lentiginous melanoma. Clin Lab Med. 2011; 31(2): 281-8.
[70] Porras BH, Cockerell CJ. Cutaneous malignant melanoma: classification and clinical
diagnosis. Semin Cutan Med Surg. 1997; 16(2): 88-96.
[71] Miranda BH, Haughton DN, Fahmy FS. Subungual melanoma: An important tip. J
Plast Reconstr Aesthet Surg. 2012; 23.
[72] Rogers RS 3rd, Gibson LE. Mucosal, genital, and unusual clinical variants of melano‐
ma. Mayo Clin Proc. 1997; 72(4): 362-6.
[73] Seetharamu N, Ott PA, Pavlick AC. Mucosal melanomas: a case-based review of the
literature. Oncologist. 2010; 15(7): 772-81.
[74] Paradela S, Fonseca E, Prieto VG. Melanoma in children. Arch Pathol Lab Med. 2011;
135(3): 307-16.
[75] Pustišek N, Situm M, Mataija M, Vurnek Živković M, Bolanča Z. Malignant melano‐
ma in childhood and adolescence. J Eur Acad Dermatol Venereol. 2012; 23.
[76] Lens MB, Newton-Bishop JA, Boon AP. Desmoplastic malignant melanoma: a sys‐
tematic review. Br J Dermatol. 2005; 152(4): 673-8.
[77] Rongioletti F, Smoller BR. Unusual histological variants of cutaneous malignant mel‐
anoma with some clinical and possible prognostic correlations. J Cutan Pathol. 2005;
32(9): 589-603.
[78] Magro CM, Crowson AN, Mihm MC. Unusual variants of malignant melanoma.
Mod Pathol. 2006; 19 Suppl 2: 41-70.
[79] Jain S, Allen PW. Desmoplastic malignant melanoma and its variants. A study of 45
cases. Am J Surg Pathol. 1989; 13(5): 358-73.
[80] Saluja A, Money N, Zivony DI, Solomon AR. Angiotropic malignant melanoma: a
rare pattern of local metastases. J Am Acad Dermatol. 2001; 44(5): 829-32.
[81] Diwan AH, Lazar AJ. Nevoid melanoma. Clin Lab Med. 2011; 31(2): 243-53.
[82] Steiner A, Konrad K, Pehamberger H, Wolff K.Verrucous malignant melanoma. Arch
Dermatol. 1988; 124(10): 1534-7.
[83] Kirkham N.Small cell melanoma. Histopathology. 2002; 40(2): 196-8.
[84] Kamino H.Spitzoid melanoma. Clin Dermatol. 2009; 27(6): 545-55.
[85] Lee L, Zhou F, Simms A, et al. Metastatic balloon cell malignant melanoma: a case
report and literature review. Int J Clin Exp Pathol. 2011; 4(3): 315-21
[86] Hocar O, Le Cesne A, Berissi S, et al. Clear cell sarcoma (malignant melanoma) of
soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract. 2012;
2012:984096.
[87] Schwartz RA. Skin Cancer Recognition and Management. 2nd Ed. Massachusetts,
Blackwell Publishing, 2008; 152-199.
Highlights in Skin Cancer118
[88] Nouri K. Skin Cancer. New York, Mc Graw Hill, 2008; 140-167.
[89] Choi JN, Hanlon A, Leffell D. Melanoma and nevi: detection and diagnosis. Curr
Probl Cancer 2011; 35: 138-161.
[90] van Kempen LC. 5th Canadian Melanoma Conference: research frontiers. Expert Rev
Anticancer Ther 2011; 11: 845-848.
[91] Rolfe HM. Accuracy in skin cancer diagnosis: a retrospective study of an Australian
public hospital dermatology department. Australas J Dermatol 2012; 53: 112-117.
[92] BJ Nickoloff. The Many Molecular Mysteries of Melanoma. Melanoma Techniques
and Protocols Molecular Diagnosis, Treatment, and Monitoring. Ed. BJ Nickoloff. To‐
towa, Humana Press; 1-14.
[93] Harris K, Florell SR, Papenfuss J, Kohlmann W, Jahromi M, Schiffman JD, et all. Mel‐
anoma mimic: a case of multiple pagetoid Spitz nevi. Arch Dermatol 2012; 148:
370-374.
[94] D'Ath P, Thomson P. Superficial spreading melanoma. BMJ. 2012; 344.
[95] Liebman TN, Rabinovitz HS, Balagula Y, Jaimes-Lopez N, Marghoob AA. White shi‐
ny structures in melanoma and BCC. Arch Dermatol 2012; 148: 146.
[96] Yang GB, Barnholtz-Sloan JS, Chen Y, Bordeaux JS. Risk and survival of cutaneous
melanoma diagnosed subsequent to a previous cancer. Arch Dermatol 2011; 147:
1395-1402.
[97] Liu Z, Sun J, Smith L, Smith M, Warr R. Distribution quantification on dermoscopy
images for computer-assisted diagnosis of cutaneous melanomas. Med Biol Eng
Comput 2012; 50: 503-513.
[98] Scolyer RA, Thompson JF, Stretch JR, Sharma R, McCarthy SW. Pathology of melano‐
cytic lesions: new, controversial, and clinically important issues. J Surg Oncol 2004;
86: 200-211.
[99] Bowen GM, Bowen AR, Florell SR. Lentigo maligna: one size does not fit all. Arch
Dermatol 2011; 147: 1211-1213.
[100] Kvaskoff M, Siskind V, Green AC. Risk factors for lentigo maligna melanoma com‐
pared with superficial spreading melanoma: a case-control study in Australia. Arch
Dermatol 2012; 148: 164-170.
[101] Pralong P, Bathelier E, Dalle S, Poulalhon N, Debarbieux S, Thomas L. Dermoscopy
of lentigo maligna melanoma: report of 125 cases. Br J Dermatol 2012 doi: 10.1111
[102] Moreno M, Schmitt RL, Lang MG, Gheno V. Epidemiological profile of patients with
cutaneous melanoma in a region of southern Brazil. J Skin Cancer 2012; 2012: 917346.
[103] Lee HY, Chay WY, Tang MB, Chio MT, Tan SH. Melanoma: differences between
Asian and Caucasian patients. Ann Acad Med Singapore 2012; 41: 17-20.
Current Management of Malignant Melanoma: State of the Art
http://dx.doi.org/10.5772/55304
119
[104] Chow WT, Bhat W, Magdub S, Orlando A. In situ subungual melanoma: Digit sal‐
vaging clearance. J Plast Reconstr Aesthet Surg 2012; 1-3.
[105] Bravo Puccio F, Chian C. Acral junctional nevus versus acral lentiginous melanoma
in situ: a differential diagnosis that should be based on clinicopathologic correlation.
Arch Pathol Lab Med 2011; 135: 847-852.
[106] Rashid OM, Schaum JC, Wolfe LG, Brinster NK, Neifeld JP. Prognostic variables and
surgical management of foot melanoma: review of a 25-year institutional experience.
ISRN Dermatol 2011; 2011: 384729.
[107] Ramos JA, Ramos WE, Ramos CV. Melanoma of the female urethra. Indian J Urol
2011; 27: 448-450.
[108] Hajar-Serviansky T, Gutierrez-Mendoza D, Galvan IL, Lammoglia-Ordiales L, Mos‐
queda-Taylor A, Hernandez-Cázares Mde L, Toussaint-Caire S. A case of oral mucos‐
al melanoma. Clinical and dermoscopic correlation. J Dermatol Case Rep 2012; 6: 1-4.
[109] Crowson AN, Magro CM, Barnhill RL, Mihm MC. Pathology. Cutaneous Melanoma.
Ed. Balch CM, Houghton AN, Sober AJ, Soong S. 4th Edition. Missouri, Quality Med‐
ical Publishing, 2003; 171-206.
[110] Hung CT, Wu BY. Cutaneous combined desmoplastic melanoma. Indian J Dermatol
Venereol Leprol 2012; 78: 230.
[111] Fish LM, Duncan L, Gray KD, Bell JL, Lewis JM. Primary cutaneous melanoma aris‐
ing in a long-standing irradiated keloid. Case Rep Surg 2012; 2012: 165319.
[112] Koc MK, Sudogan S, Kavala M, Kocaturk E, Büyükbabani N, Altintas S. Desmoplas‐
tic spitz naevus can be mistaken for desmoplastic malignant melanoma and dermato‐
fibroma. Acta Derm Venereol 2011; 91: 74-75.
[113] Weedon D. Lentigines, nevi, and melanomas. Weedon’s Skin Pathology. 3rdEd.
Churchill Livingstone Elsevier. 2010; 709- 756.
[114] Mckee PH, Calonje E, Granter SR. Melanoma. Pathology of the skin with clinical cor‐
relation. 3rd Ed. Elsevier Mosby. 2005; 1309-1356.
[115] Smalberger GJ, Siegel DM, Khachemoune A. Lentigo maligna. Dermatol Ther 2008;
21: 439-446.
[116] Reed JA, Shea CR. Lentigo maligna: melanoma in situ on chronically sun-damaged
skin.Arch Pathol Lab Med 2011; 135: 838-841.
[117] Duncan LM. The classification of cutaneous melanoma. Hematol Oncol Clin North
Am 2009; 23: 501-513.
[118] Su WP. Malignant melanoma: basic approach to clinicopathologic correlation. Mayo
Clin Proc 1997; 72: 267-272.
[119] Payette MJ, Katz M 3rd, Grant-Kels JM. Melanoma prognostic factors found in the
dermatopathology report. Clin Dermatol 2009; 27: 53-74.
Highlights in Skin Cancer120
[120] Stoff B, Salisbury C, Parker D, O'Reilly Z, Wald F. Dermatopathologyof skin cancer
in solid organ transplant recipients. Transplant Rev 2010; 24: 172-189.
[121] Phan A, Touzet S, Dalle S, Ronger-Savlé S, Balme B, Thomas L. Acral lentiginous
melanoma: histopathological prognostic features of 121 cases. Br J Dermatol 2007;
157: 311-318.
[122] Kim YC, Lee MG, Choe SW, Lee MC, Chung HG, Cho SH. Acral lentiginous melano‐
ma: an immunohistochemical study of 20 cases. Int J Dermatol 2003; 42: 123-129.
[123] Stalkup JR, Orengo IF, Katta R. Controversies in acral lentiginous melanoma. Derma‐
tol Surg 2002; 28: 1051-1059.
[124] Hollmig ST, Sachdev R, Cockerell CJ, Posten W, Chiang M, Kim J. Spindle cell neo‐
plasms encountered in dermatologic surgery: a review. Dermatol Surg 2012; 38:
825-850.
[125] Murali R, Loughman NT, McKenzie PR, Watson GF, Thompson JF, Scolyer RA. Cyto‐
logic features of metastatic and recurrent melanoma in patients with primary cutane‐
ous desmoplastic melanoma. Am J Clin Pathol 2008; 130: 715-723.
[126] Chen JY, Hruby G, Scolyer RA, Murali R, Hong A, Fitzgerald P et al. Desmoplastic
neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008; 113:
2770-2778.
[127] Busam KJ. Desmoplastic melanoma. Clin Lab Med 2011; 31: 321-330.
[128] Kay PA, Pinheiro AD, Lohse CM, Pankratz VS, Olsen KD, Lewis JE et al. Desmoplas‐
tic melanoma of the head and neck: histopathologic and immunohistochemical study
of 28 cases. Int J Surg Pathol 2004; 12: 17-24.
[129] Manganoni AM, Farisoglio C, Bassissi S, Braga D, Facchetti F, Ungari M et al. Desmo‐
plastic melanoma: report of 5 cases. Dermatol Res Pract. 2009; 2009: 679010.
[130] Chorny JA, Barr RJ, Kyshtoobayeva A, Jakowatz J, Reed RJ. Ki-67 and p53 expression
in minimal deviation melanomas as compared with other nevomelanocytic lesions.
Mod Pathol 2003; 16: 525-529.
[131] Podnos YD, Jimenez JC, Zainabadi K, Jakowatz JG, Barr RJ. Minimal deviation mela‐
noma. Cancer Treat Rev 2002; 28: 219-221.
[132] Hantschke M, Mentzel T, Kutzner H. Follicular malignant melanoma: a variant of
melanoma to be distinguished from lentigo maligna melanoma. Am J Dermatopathol
2004; 26: 359-363.
[133] Hu SW, Tahan SR, Kim CC. Follicular malignant melanoma: a case report of a meta‐
static variant and review of the literature. J Am Acad Dermatol 2011; 64: 1007-1010.
[134] Ivan D, Prieto VG. An update on reporting histopathologic prognostic factors in mel‐
anoma. Arch Pathol Lab Med 2011; 135: 825-829.
[135] Garbe C, Eigentler TK, Bauer J, Blödorn-Schlicht N, Fend F, Hantschke M et al. Histo‐
pathological diagnostics of malignant melanoma in accordance with the recent AJCC
Current Management of Malignant Melanoma: State of the Art
http://dx.doi.org/10.5772/55304
121
classification 2009: Review of the literature and recommendations for general prac‐
tice. J Dtsch Dermatol Ges 2011; 9: 690-699.
[136] Piris A, Mihm MC Jr, Duncan LM. AJCC melanoma staging update: impact on der‐
matopathology practice and patient management. J Cutan Pathol 2011; 38: 394-400.
[137] Piris A, Mihm MC Jr. Progress in melanoma histopathology and diagnosis. Hematol
Oncol Clin North Am 2009; 23: 467-480.
[138] Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A et al. Diagnosis and
treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J
Cancer 2010; 46: 270-283.
[139] Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical charac‐
teristics of melanoma.J Cutan Pathol 2008; 35:433-444.
[140] Puri PK, Forman SB, Ferringer T, Elston D. S100A6 immunohistochemical staining
for spindle cell and desmoplastic melanomas. J CutanPathol 2008; 35:256-257.
[141] Prieto VG, Shea CR. Use of immunohistochemistry in melanocytic lesions. J Cutan
Pathol 2008; 35 Suppl 2: 1-10.
[142] Hong A, Fogarty G. Role of radiation therapy in cutaneous melanoma. Cancer J.
2012; 18: 203-207.
[143] Larkin JM, Fisher RA, Gore ME. Adjuvant interferon therapy for patients at high risk
for recurrent melanoma: An updated systematic review. Clin Oncol. 2012; 24:
410-412.
[144] Kaufman HL. Vaccines for melanoma and renal cell carcinoma. Semin Oncol. 2012;
39: 263-275.
[145] Damian DL, Saw RP. Dramatic regression of cutaneous, nodal, and visceral melano‐
ma metastases. J Am Acad Dermatol. 2011; 65: 665-666.
[146] Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and in‐
terleukin-2 in patients with advanced melanoma. N Engl J Med. 2011; 364: 2119–2127.
[147] Abdelmalek M, Loosemore MP, Hurt MA, Hruza G. Geometric staged excision for
the treatment of lentigo maligna and lentigo maligna melanoma: A long-term experi‐
ence with literature review. Arch Dermatol. 2012; 148: 599-604.
[148] Szabo A, Osman RM, Bacskai I, Kumar BV, Agod Z, Lanyi A, Gogolak P, Rajnavolgyi
E. Temporally designed treatment of melanoma cells by ATRA and polyI: C results
in enhanced chemokine and IFNβ secretion controlled differently by TLR3 and
MDA5. Melanoma Res. 2012 [Epub ahead of print]
[149] Burmeister B, Henderson M, Thompson J, et al. Adjuvant radiotherapy improves re‐
gional (lymph node field) control in melanoma patients after lymphadenectomy: re‐
sults of an intergroup randomized trial. Int J Radiat Oncol Biol Phys. 2009; 75: 1-2.
Highlights in Skin Cancer122
[150] Arbiser JL, Bips M, Seidler A, Bonner MY, Kovach C. Combination therapy of imiqui‐
mod and gentian violet for cutaneous melanoma metastases. J Am Acad Dermatol.
2012; 67: 81-83.
[151] Mohan M, Sukhadia VY, Pai D, Bhat S. Oral malignant melanoma: systematic review
of literature and report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol.
2012. [Epub ahead of print]
[152] Hardin RE, Lange JR. Surgical treatment of melanoma patients with early sentinel
node involvement. Curr Treat Options Oncol. 2012. [Epub ahead of print]
[153] Neier M, Pappo A, Navid F. Management of melanomas in children and young
adults. J Pediatr Hematol Oncol. 2012; 34: 51-54.
[154] Smalley KS, McArthur GA. The current state of targeted therapy in melanoma: this
time it's personal. Semin Oncol. 2012; 39: 204-214.
[155] Mozzillo N, Caracò C, Mori S, Di Monta G, Botti G, Ascierto PA, Caracò C, Aloj L.
Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the
cheek in a patient with melanoma. J Transl Med. 2012; 10: 131.
[156] Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, Demarini DJ et al.
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a
phase 1 dose-escalation trial. Lancet Oncol. 2012; 13: 782-789.
[157] Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, Long GV,
Fernandez-Peñas P. Cutaneous manifestations of dabrafenib (GSK2118436): A selec‐
tive inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol.
2012; 10: 1365-1367.
[158] Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive
lethal characteristics from a 30-year clinical experience. Ann Surg. 2003; 238(4):
528-35.
[159] Krathen M. Malignant melanoma: advances in diagnosis, prognosis, and treatment.
Semin Cutan Med Surg. 2012; 31(1): 45-9.
[160] Balch CM, Gershenwald JE, Soong SJ et al. Final Version of 2009 AJCC Melanoma
Staging and Classification. J Clin Oncol 2009; 27(36): 6199-206.
[161] Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Ger‐
shenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL,
Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final Version of the
American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J
Clin Oncol 2001; 19: 3635-3648.
[162] Kruijff S, Bastiaannet E, Francken AB, Schaapveld M, van der Aa M, Hoekstra HJ. Br
J Cancer. Breslow thickness in the Netherlands: a population-based study of 40 880
patients comparing young and elderly patients.2012; 24;107(3):570-4.
Current Management of Malignant Melanoma: State of the Art
http://dx.doi.org/10.5772/55304
123
[163] Pflugfelder A, Weide B, Eigentler TK, Forschner A, Leiter U, Held L, Meier F, Garbe
C. Incisional biopsy and melanoma prognosis: Facts and controversies.Clin Derma‐
tol. 2010; 28(3): 316-8.
[164] Owen SA, Sanders LL, Edwards LJ, Seigler HF, Tyler DS, Grichnik JM. Identification
of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Cancer. 2001; 1; 91(5): 983-91.
[165] Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, Colman
MH, Zhang Y. Tumor mitotic rate is a more powerful prognostic indicator than ul‐
ceration in patients with primary cutaneous melanoma: an analysis of 3661 patients
from a single center. Cancer. 2003; 15;97(6): 1488-98.
[166] Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamination. Am J Clin Pathol.
2007; 127(3): 380-4.
[167] Lee S, Margolin K. Tumor-Infiltrating Lymphocytes in Melanoma. Curr Oncol Rep.
2012 Aug 10.
[168] Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP,
Thompson JF. Tumor-infiltrating lymphocyte grade is an independent predictor of
sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin
Oncol. 2012; 20; 30(21): 2678-83.
[169] Wilmott J, Haydu L, Bagot M, Zhang Y, Jakrot V, McCarthy S, Lugassy C, Thompson
J, Scolyer R, Barnhill R. Angiotropism is an independent predictor of microscopic sat‐
ellites in primary cutaneous melanoma. Histopathology. 2012; 30: 1365-2559.
[170] Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Hölzel D, Coebergh JW, En‐
gel J. Gender differences in melanoma survival: female patients have a decreased risk
of metastasis. J Invest Dermatol. 2011; 131(3): 719-26.
[171] Bradford PT, Anderson WF, Purdue MP, Goldstein AM, Tucker MA. Rising melano‐
ma incidence rates of the trunk among younger women in the United States. Cancer
Epidemiol Biomarkers Prev. 2010; 19(9): 2401-6.
[172] Bulliard JL, Cox B. Cutaneous malignant melanoma in New Zealand: trends by ana‐
tomical site, 1969-1993. Int J Epidemiol. 2000; 29(3): 416-23.
[173] Barnhill RL, Lugassy C. Angiotropic malignant melanoma and extravascular migra‐
tory metastasis: description of 36 cases with emphasis on a new mechanism of tu‐
mour spread. Pathology. 2004; 36(5): 485-90.
[174] Ryszard M. Pluta, MD, PhD: Melanoma. JAMA 2011;305:2368.
[175] Riker AI, Zea N, Trinh T: The epidemiology, prevention and detection of melanoma.
The Ochsner Journal 2010; 10: 56-65.
[176] Halpern AC, Marghoob AA, Sober AJ: Clinical characteristics. In: Cutaneous Melano‐
ma. Balch CM, Houghton AN, Sober AJ, Soong S. Eds. 4th Edition. Canada, Quality
Medical Publishing 2003; 7: 135-162.
Highlights in Skin Cancer124
[177] Jou PC, Feldman RJ, Tomecki KJ: UV protection and sunscreens: what to tell patients.
Cleve Clin J Med 2012; 79: 427-436.
[178] Sefton E, Glazebrook C, Garrud P, Zaki I: Educating patients about makignant mela‐
noma: computer-assisted learning in a pigmented lesion clinic. Br J Dermatol 2000;
142: 66-71.
[179] Berwick M, Begg CB, Fine JA, et. al. Screening for cutaneous melanoma by skin self-
examination. J Natl Cancer Inst 1996; 88: 17.
[180] Mujumdar UJ, Hay JL, Monroe-Hinds YC, Hummer AJ, Begg CB, Wilcox HB, Olive‐
ria SA, Berwick M: Sun protection and skin-self examination in melanoma survivors.
Psychooncology 2009; 18: 1106-1115.
[181] Swetter SM, Geller AC, Kirkwood JM. Melanoma in the older person. Oncology (Wil‐
liston Park). 2004; 18: 1187-96; discussion 1196-7.
[182] Uliasz A, Lebwohl M: Patient education and regular surveillance results in earlier di‐
agnosis of second primary melanoma. Int J Dermatol 2007; 46: 575-577.
[183] Constantinidou A, Afuwape SA, Linsell L, Hung T, Acland K, Healy C, Ramirez AJ,
Harries M: Informational needs of patients with melanoma and their views on the
utility of investigative tests. Int J Clin Pract 2009; 63: 1595-1600.
[184] Husson O, Holterhues C, Mols F, Nijsten T, van de Poll-Franse LV: Melanoma survi‐
vors are dissatisfied with perceived information about their diagbosis, treatment and
foolow-up care. Br J Dermatol 2010; 163: 879-881.
Current Management of Malignant Melanoma: State of the Art
http://dx.doi.org/10.5772/55304
125

